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SUMMARY
Over the last thirty years, effective and relatively safe control of 
hypertension has become possible. As a result, less severe forms of 
high blood pressure now warrant treatment. Such treatment needs to 
be acceptable to the patient and free from long-term toxicity.
The angiotensin converting enzyme (ACE) inhibitors offer the 
possibility of improved tolerability and a novel mechanism of action. 
After review of the renin-angiotensin system, the clinical 
pharmacology of the two currently available ACE inhibitors is 
discussed. Captopril and enalapril have been demonstrated to be 
effective treatments in hypertension and cardiac failure. Both drugs 
may cause significant side effects and so there is justification for 
investigation of a similar compound which has an excellent safety 
profile in laboratory studies.
The steps involved in the transfer of drugs from the animal 
laboratory to early clinical studies in man are then discussed.
Perindopril is the esterifled form of a potent and long-acting ACE 
inhibitor, S-9780; it is a prodrug which relies on bioactivation in 
vivo. The studies described in this thesis include some of the 
earliest administrations of perindopril to man and the first clinical 
trial involving S-9780.
In the earliest dose-ranging study, 36 norraotensive volunteers, in 
parallel groups of 6 subjects, were given perindopril (1 to 16 mg)
20
orally for 7 consecutive days. The drug was well tolerated and no 
sign of toxicity was detected. Blood pressure was lowered by active 
treatment (14/11 mmHg 6 hours after 16 mg) with only a slight rise in 
heart rate (15 beats.min ^) after chronic treatment with 16 mg.
Plasma ACE was inhibited and plasma renin activity was elevated in a 
dose-related pattern. Plasma aldosterone levels fell. The maximum 
effect occurred after 4 - 6  hours and 60% inhibition of plasma ACE 
persisted 24 hours after dosing with 8 and 16 mg. Plasma 
catecholamines were unchanged.
A double blind crossover study in 8 normotensive volunteers 
demonstrated that intravenous administration of the active metabolite 
of perindopril, S-9780, was well tolerated and apparently safe. 
Maximal inhibition of plasma ACE occurred after only 1 mg. A 
dose-related rise in plasma renin activity occurred but no effect on 
plasma aldosterone was detected. Blood pressure was lowered by 8/14 
mmHg 3 hours after 4 mg of S-9780 intravenously with no change in 
heart rate or plasma catecholamines.
The effect of perindopril on autonomic function was assessed in a 
double blind, placebo controlled, crossover study in 10 normotensive 
males. Eight milligrammes given orally lowered blood pressure 
without a change in heart rate. Perindopril enhanced the vagally 
mediated heart rate variation with deep breathing. There was no 
impairment of the response to either bicycle exercise at 175 W for 5 
minutes or isometric handgrip. The pressor response to cold and the 
response to the Valsalva manoeuvre were unaltered. These results 
suggested that the absence of tachycardia after perindopril might be 
in part related to enhanced parasympathetic tone.
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In a single blind, placebo controlled study in seven hypertensive 
patients treated for one month, tolerability was excellent. Blood 
pressure was lowered from 164/93 mmHg to 145/84 mmHg by 4 mg of 
perindopril and after one month remained 142/82 mmHg. Neither 
postural hypotension nor tachycardia occurred. The biochemical 
effects were comparable to those in the volunteers.
Plasma S-9780 levels were determined by an enzyme inhibition assay 
following treatment with oral perindopril and intravenous S-9780.
The kinetics were linear and were not altered by repeated dosing.
The intravenous data showed triphasic decay with a terminal half-life 
of over 30 hours; despite this, the accumulation half-life after 
repeated dosing was under 9 hours. The controversy over the 
pharmacokinetics of ACE inhibitors is acknowledged. Bioavailability 
of S-9780 after perindopril given orally was 15%. The kinetics of 
S-9780 in man corresponded to the kinetics in the laboratory animals 
which were used for the preclinical studies.
Plasma ACE inhibition was related to plasma drug concentrations
following intravenously administered S-9780: a close correlation was
obtained using the Hill equation to describe the relationship. The
plasma concentration of S-9780 which produced 50% inhibition of
-1
plasma ACE was 1.8 + 0.9 ng.ml
After oral dosing, the peak effect on ACE lagged behind peak plasma 
S-9780 concentration by several hours. A concentration-effect model 
allowed description of this relationship. Using the parameters of 
the model, it was shown that the sensitivity of plasma ACE to S-9780
22
diminished slightly with repeated dosing. More rapid onset and 
offset of action also occurred.
In conclusion, perindopril was well tolerated by over 50 subjects 
treated for up to one month, with no evidence of toxicity. The 
diacid metabolite, S-9780, is a potent and long acting inhibitor of 
plasma ACE in humans, with predictable and dose-related effects on 
the renin-angiotensin system. Perindopril possesses useful 
blood pressure lowering activity without causing postural hypotension 
or tachycardia. It enhances parasympathetic activity: this latter
property is probably a feature of all ACE inhibitors.
The kinetics of S-9780 are linear. The decay in plasma levels is 
triphasic with a terminal half-life in excess of 30 hours. Despite 
this, accumulation of S-9780 does not occur after 43 - 60 hours 
during repeated oral dosing. The bioavailability of S-9780 is about 
15% and the concentration which produces 50% inhibition of plasma ACE 
in man is 1.8 + 0.9 ng.ml \  The concentration-effect 
relationship between S-9780 and ACE inhibition is complex following 
oral administration of perindopril. Changes occur after repeated 
dosing which suggest diminished sensitivity to the drug, probably as 
a result of induction of plasma ACE.
These early studies with perindopril reveal how investigations in 
normal volunteers can provide information about the likely response 
of hypertensive patients to new ACE inhibitors. The study in 
patients confirms the usefulness of the volunteer studies and 
demonstrates that perindopril is worthy of more extensive evaluation 
in essential hypertension.
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CHAPTER 1
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BACKGROUND AND SCOPE OF THE THESIS
This chapter deals firstly with the background to the treatment of 
high blood pressure, continues with a discussion of the drugs which 
are in current use, concentrating particularly on the angiotensin 
converting enzyme inhibitors, and then moves on to consideration of 
the early clinical investigation of new drugs. Finally, an outline 
is given of the chapters which follow: in these, the early clinical
investigation of a new angiotensin converting enzyme inhibitor, 
perindopril, is described.
1.1 TREATMENT OF HYPERTENSION
This century has seen remarkable advances in the understanding and 
management of high blood pressure. The most major of these concern, 
firstly, the development of satisfactory noninvasive means of 
measuring the blood pressure; secondly, identification of the 
contribution of hypertension to morbidity and mortality; and finally, 
recognition that treatment of severe hypertension results in greatly 
reduced morbidity and mortality. Thus, since the late 1950's, clear 
benefits from treatment of malignant hypertension even with rather 
unsatisfactory antihypertensive agents have been acknowledged 
(18,87).
Over the following 30 years the advances have been less dramatic but
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of far greater benefit to a greater number of patients. In 1967, the 
Veterans Administration Cooperative Study Group on Antihypertensive 
Agents’ trial of the effects of treatment on morbidity in less severe 
hypertension (206) demonstrated striking benefit of treatment to 
patients with diastolic pressures of over 115 mmHg. The same trial 
later showed that the benefit extended down to levels of pressure 
between 90 and 114 mmHg (207) and that the potential benefit was 
related to the level of pretreatment blood pressure. Active 
treatment halved the hypertension-related mortality in this group and 
had an even more profound effect on the morbidity. The narrow 
selection criteria for recruitment to this study relative to the 
at-risk population and the failure to demonstrate a statistically 
significant reduction in coronary events were amongst the reasons 
that further trials were considered necessary.
The results of the Hypertension and Follow-up Program Cooperative 
Group’s trial (101) clarified some outstanding points. The benefit of 
treatment of diastolic blood pressures which exceed 90 mmHg was shown 
to apply to the whole population rather than just middle aged males.
A reduction in deaths due to acute myocardial infarction occurred in 
the more intensively treated ’stepped care’ group, although a 
decrease in deaths due to noncardiovascular diseases does raise the 
question of whether closer medical supervision rather than improved 
control of blood pressure may have accounted for some of the 
difference. There is, however, strong support for these results from 
other studies.
The Australian Therapeutic Trial in Mild Hypertension confirmed the 
benefit of treatment to a group of patients aged 30 - 69 years with
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diastolic blood pressures of 95 - 104 mmHg (11) but also showed that 
the benefit extended to include those patients aged 65 - 74 years 
(149). In the light of these and other trials' results, a combined 
meeting of the World Health Organisation and the International 
Society of Hypertension in 1982 endorsed guidelines (219) which 
include active treatment for patients who have diastolic blood 
pressures consistently above 95 mmHg and for those with pressures 
between 90 and 95 mmHg who have additional risk factors.
The situation is complicated, however, by two other factors. The 
first of these is that a small percentage benefit spread over the 
large majority of patients who have mild hypertension will result in 
the saving of many more lives than a large percentage benefit 
restricted to a limited group of patients who have severe 
hypertenson. Thus, whilst in epidemiological terms there is sound 
evidence that morbidity and mortality will be reduced by such a 
strategy, it is nevertheless clear that the majority of patients who 
will be treated for the remaining duration of their lives will derive 
no benefit from the intervention. The second factor is related to 
the first: since the initial reports of benefit from
antihypertensive therapy, the available drug regimens have been 
revolutionised; the modern treatments are not yet free from side 
effects, however, and long term administration may yet reveal new 
problems with some agents which are currently thought to be 
satisfactory.
The epidemiologist would argue in favour of a general approach, using 
the best available regimens to control blood pressure in all 
identified at-risk groups. He would stress the need for screening
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and preventive measures on a population basis. The physician is 
aware that he must balance an individual’s risk profile against his 
response to treatment and possible side effects. The patient will 
inevitably and rightly wish to be involved in the decisions. For the 
clinical pharmacologist, the issue must be to aid in the development 
of new agents which have improved risk/efficacy profiles and to 
clarify the mechanisms of action and of toxicity of currently 
available drugs.
1.2 DRUGS USED IN THE TREATMENT OF HYPERTENSION
The preceding discussion has outlined the need for well tolerated, 
safe and effective antihypertensive drugs. The agents which are 
currently in use are now examined. They are considered under broad 
headings: the /3-adrenoceptor antagonists, the diuretics, the
vasodilators, the centrally acting drugs and the angiotensin 
converting enzyme inhibitors, although discussion of the last group 
is reserved for the following section of the chapter. For each 
group, the mode of action is described. Clinical features are 
compared and contrasted, both across and within the groups, with 
particular emphasis on the safety and tolerance of the drugs. The 
need for further antihypertensive drugs is justified.
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/3-adrenoceptor Antagonists (/3-blockers )
General
Following the fortuitous discovery that the /3-blockers lowered blood 
pressure, propranolol was confirmed as a useful antihypertensive 
agent in the 1960’s (168). Many compounds have become available and 
these are now amongst the most widely used cardiovascular drugs.
Mode of Action
Adrenergic receptors were classified in to a and /3 sub-types by 
Alquhist in 1948 (1). Since then, the /3-receptors have been 
further studied and found to comprise two types, i.e. /3^ and 
The -receptors are found mainly in cardiac muscle, where they 
mediate the positive inotropic and chronotropic effects of the 
catecholamines, and in adipose tissue. The ^^-receptors are 
found in the bronchi, pancreas and peripheral vasculature: in this
site they produce vasodilatation. To a certain extent, therefore, 
the mode of action of the ^-blockers can be predicted from the
receptor distribution and function.
Acute administration reduces heart rate and cardiac output (195). A 
compensatory initial rise in peripheral resistance prevents a large 
initial fall in blood pressure (86) but subsequent adjustment to a 
lower level of pressure appears to occur. The /3-blockers which 
possess partial agonist activity may act differently: whereas the
pure antagonists affect blood pressure by an action on cardiac 
receptors, pindolol directly lowers vascular resistance (190). There 
is some evidence that the /3-blockers may act via central mechanisms
(124). Finally, although /3-blockers depress renin activity, there
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does not appear to be any association between this action and their 
antihypertensive effect.
Efficacy
The ^-blockers cause moderate and generally predictable falls in 
blood pressure, often indistinguishable from the effect of the 
thiazide diuretics (142). Once daily treatment is usually adequate.
Clinical Features
The ^-blockers are not a homogeneous group. Partial agonism at 
/3-receptors has already been mentioned as one additional feature of 
some ^-blockers. Other separate features include membrane 
stabilising activity, relative selectivity for the /^-receptor, 
hydrophilicity and hepatic metabolism.
Dose selection is aided when first pass metabolism does not occur. 
Hydrophilicity reduces the amount of drug which crosses the 
blood-brain barrier and thus minimises the risk of sedation and 
nightmares. Cardioselectivity confers relative freedom from 
bronchospasm (47) and easier reversal by bronchodilators, as well as 
reduced risk of a pressor response to smoking (201) and to 
hypoglycaemia (45). Membrane stabilising activity is probably not 
relevant at the doses used clinically. Sotalol does, however, 
possess class III antiarrhythmic activity. Partial agonism offers 
theoretical advantages when heart failure or peripheral vascular 
disease are present, but convincing evidence of its practical benefit 
is awaited.
The side effects of the /3-blockers are well recognised.
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Bronchospasm, cardiac failure, heart block and peripheral vascular 
disease are major contraindications as each can be exacerbated.
During routine clinical use these conditions can usually be 
identified easily before treatment. Thus, the side effects which are 
actually encountered are milder: the MRC trial (141) reported
increased incidences of Raynaud's phenomenon, dyspnoea, rash, 
lethargy, nausea, dizziness and headache after propranolol.
Reversible impotence was also noted, though the incidence was about 
half of that seen after bendrofluazide (i.e. 13% after direct 
questioning). The effects of the /8-blockers on lipid metabolism 
remain the subject of controversy. Certainly, adverse effects on 
high density lipoproteins and triglycerides have been reported with 
several of these drugs (179).
Counterbalancing the potential harmful effects of long term 
^-blockade is the firm evidence that these drugs do have a secondary 
preventive action following myocardial infarction (93,154). It is 
pure supposition, but very tempting, to infer that they may be 
equally useful as primary preventive agents. The usefulness of the 
drugs as antianginal agents is beyond doubt.
Conclusions
This group of drugs having disparate properties and a common effect 
has now become widely used for cardiovascular indications. 
Contraindications are generally easily recognised and side effects 
are otherwise fairly minor though not infrequent. The potential 
cardioprotective effects have led to enthusiasm for choosing a 
/3-blocker as first line therapy in hypertension. Nevertheless, there 
remains a cohort of patients who are unsuited to these drugs or in
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whom a second drug is required.
Diuretics
General
The diuretics are drugs which share the property of promoting renal 
excretion of salts, and perhaps fortuitously, the property of
lowering arterial blood pressure. There is wide variation in the
potency and other pharmacological features of the diuretics. The 
most useful classification relies on their respective sites of action 
in the kidney. Thus, there are three groups in common use: the
thiazides, which inhibit sodium reabsorption at the distal convoluted 
tubule (115); the loop diuretics, so called because they reduce 
sodium reabsorption in the ascending limb of the loop of Henle; and 
the potassium sparing diuretics, which are physiological antagonists 
(e.g. amiloride) or pharmacological antagonists (e.g. spironolactone) 
of aldosterone and thus prevent the exchange of potassium for sodium 
in the distal tubule and collecting duct (83). The diuretics which 
are most widely used in hypertension are the thiazides. Nearly 30
years of use illustrate their importance in this field.
Mode of Action
Clearly, prolonged diuretic exposure results in a resetting of the 
renal threshold for salt and water retention and in a reduction of 
intravascular and probably intracellular volume. This certainly 
contributes to the hypotensive action, but does not entirely explain 
it, since restitution of plasma volume will not completely restore 
the blood pressure (40) and since the dose response relationships
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for diuresis and antihypertensive effect are not comparable (28). A 
combination of effects on vascular smooth muscle contractility (199), 
structural changes in resistance vessels due to alterations in 
intracellular salt and water (199) and the changes in extracellular 
volume is probably responsible for the antihypertensive effect.
Efficacy
The effect of the drugs is moderate, with a mean fall of about 12/8 
mmHg (145). There does not appear to be any risk of precipitating 
sudden hypotension. In comparison with a /5-blocker, there is little 
difference in efficacy (142). It is clear that a diuretic will 
potentiate the antihypertensive action of most other groups of drugs, 
and this is one of the most useful features. The thiazides are 
claimed to be more effective than loop diuretics in lowering blood 
pressure (6), but are probably equipotent to the potassium sparing 
agents (221).
Clinical Features
The MRC trial in mild to moderate hypertension illustrates the 
clinical features of bendrofluazide (141). Both sexes had 
significantly increased incidences of impaired glucose tolerance, 
lethargy, constipation and other reactions such as nausea, dizziness 
and headache. Men had strikingly higher incidences of gout and of 
impotence. With the exception of the hyperuricaemia, the side 
effects occurred especially within the first three months of exposure 
and usually within one year. Seventeen percent of men withdrew from 
bendrofluazide treatment over 5 years, compared with 13% of the 
women. Significant rises in serum uric acid and significant falls in 
serum potassium were noted. A marginal increase in serum cholesterol
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occurred.
In contrast to the thiazide diuretics, the potassium sparing agents, 
amiloride and triamterine, have as their main side effect 
hyperkalaemia. Neither serum urate levels nor glucose metabolism is 
affected. Serum calcium, which is frequently raised by thiazides, is 
not affected by these drugs.
Spironolactone, in addition to producing hyperkalaemia, may cause 
gynaecomastia and impotence in men and menstrual disturbances in 
women due to its structural similarity to progesterone.
Conclusions
Diuretics, and particularly the thiazides, have an important role in 
hypertension management. The relatively high incidence of side 
effects in men and of biochemical changes which may increase long 
term risk does argue against first line use in all patients. For the 
patient in whom a /3-blocker is contraindicated or inadequate,
however, a diuretic is perhaps still the optimum second drug. The
potassium sparing diuretics should be reserved for individual
indications and the loop diuretics should only be used where fluid
retention or renal impairment is present.
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Vasodilators
These will be discussed under three headings: the direct
vasodilators, the a-blockers and the calcium antagonists.
Direct Vasodilators
Hydralazine, minoxidil and diazoxide are the most commonly used 
members of this group. Hydralazine was first introduced in the 
1950's but has only recently gained full recognition for its place in 
the modern regimen (137). The reasons for this are discussed below. 
Minoxidil is a more recent and very potent vasodilator. Once again, 
side effects limit its use. Diazoxide similarly is a potent 
vasodilator, but has adverse effects when used orally.
Mode of Action
These drugs all have a direct relaxant effect on vascular smooth 
muscle, which does not appear to be mediated by effects on adrenergic 
or other specific receptors. An effect on calcium channels has been 
reported with hydralazine (140) but as yet it is not recognised that 
this is the primary mechanism for its effect. The result of 
vasodilatation of the pre-capillary arterioles is a fall in vascular 
resistance. This is quite dramatic,•but is compensated for by an 
increase in sympathetic activity which increases cardiac output 
(62). In addition, marked stimulation of the renin-angiotensin 
system occurs leading to fluid retention especially with minoxidil 
(165).
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Efficacy
The vasodilating effect of these drugs is substantial, but the 
compensation which occurs limits their antihypertensive action. 
Combination with a ^-blocker and diuretic greatly improves the 
results (137) although some workers would suggest that the /J-blocker 
is superfluous in groups with poor baroreflex function, such as the 
elderly (5).
Clinical Features
The side effects of these drugs fall in to two categories. Those 
which are an extension of their pharmacological effect include 
tachycardia and fluid retention. These are not a major problem when 
the vasodilators are used in combination with the two usual first 
line drugs, a /8-blocker and a diuretic.
Hydralazine has a further side effect, however. A small percentage 
of patients develop drug induced lupus with this drug. The risk is 
directly related to the dose, but although modern lower doses, under 
150 mg per day, have led to a reduction in incidence, the syndrome 
continues to occur with an incidence of over 5% after one year's 
treatment (169). Slow acetylator status results in reduced drug 
clearance and predisposes to increased antihypertensive efficacy and 
increased risk of lupus in patients with this phenotype (164). 
Fortunately, withdrawal of the drug or even dosage reduction results 
in resolution of the syndrome, and regular monitoring of anti-nuclear 
factor titres may identify the at-risk patient before symptoms 
develop.
The unusual side effects associated with minoxidil include hirsutism
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(57) and, perhaps simply as an extension of the fluid retention, 
pericardial effusion (135). Minoxidil is recommended only for 
hypertension in men, which is resistant to standard regimes.
Diazoxide is not used orally as it may cause significant glucose 
intolerance and renal impairment (162); it remains useful when given 
intravenously in hypertensive emergencies (147).
g-blockers
Three a-blockers are used for hypertension; prazosin, phentolamine 
and phenoxybenzamine. The last of these binds covalently to 
a-receptors and is almost exclusively used for pre-operative treatment 
of phaeochromocytoma. Likewise, phentolamine is not widely used, 
although it provides rapid and reversible a-blockade when given 
intravenously. Prazosin is therefore the only widely prescribed drug 
of this class.
Mode of Action
Prazosin is a specific antagonist at the post-synaptic -receptor. 
Thus, it inhibits sympathetically mediated vasoconstriction and 
lowers total peripheral resistance.
Clinical Features
The first dose of prazosin occasionally causes profound hypotension, 
an effect which is minimised if a low starting dose is prescribed 
(78). After hydralazine, it was the most acceptable ’third drug' in 
the Clasgow 'Third Drug' Trial (137).
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Calcium Antagonists
Two classes of drug are found in this group: the pyridine
derivatives, typified by nifedipine, and the papaverine derivatives, 
such as. verapamil. They are among the most recent and most promising 
of the antihypertensive agents to become available.
Mode of Action
Smooth muscle contraction is initiated by membrane depolarisation, 
which is sodium dependent, followed by calcium influx through 
specific channels; the calcium antagonists restrict this influx.
Thus, they cause relaxation of vascular smooth muscle. There is some 
variation in the sites of action: verapamil also inhibits atrio­
ventricular conduction and the smooth muscle of the gut, whereas 
nifedipine appears more specific to vascular muscle.
Efficacy
In the usual therapeutic doses, the calcium antagonists exert moderate 
antihypertensive effects, similar to /3-blockers (64).
Clinical Features
Nifedipine has a similar effect to hydralazine on the peripheral 
vasculature and also causes mild compensatory tachycardia and oedema 
of the extremities. It does have the advantage, however, that 
coronary vasodilatation may occur and for this reason it is often 
used in the management of patients who have coexisting hypertension 
and angina pectoris. Pounding headache and a flushing sensation are 
common symptoms and the duration of action is short even when a 
sustained release formulation is employed.
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Verapamil has the disadvantages of causing constipation (123) and of 
undergoing extensive first pass metabolism in the liver, thus making 
dosage selection difficult and variable. Its effects on the 
myocardial conducting system confer the advantage over nifedipine 
that a reflex tachycardia does not occur, but toxicity may result in 
heart block, especially in the presence of /3-adrenergic blockade. 
Verapamil possesses useful antianginal activity (64).
Conclusions
In a condition characterised by increased peripheral resistance, such 
as hypertension, it would seem logical to employ vasodilator drugs. 
Homeostatic mechanisms operate which counter the fall in resistance, 
however, and which limit the effects on blood pressure and give rise 
to undesirable side effects. Future developments of these drugs may 
yet produce a compound which exhibits only the positive features of a 
compromise.
Centrally Acting Drugs 
General
Reserpine, clonidine and a-methyl dopa comprise this group. The 
first of these is undoubtedly an effective antihypertensive agent 
(206,207) but it causes marked sedation or depression, sufficient 
even to result in suicide, and is not used in Britain at present. 
Clonidine has also lost favour, primarily because it has a short 
duration of action and the propensity to cause a hypertensive crisis 
after sudden withdrawal. Alpha-methyl dopa has been in use for a
39
quarter of a century, however, and although it is gradually being 
supplanted, it remains a widely prescribed drug.
Mode of Action
After crossing the blood brain barrier, a-methyl dopa is 
decarboxylated to a-methyl noradrenaline, which acts as a false 
transmitter (90). This compound is less potent than noradrenaline 
and may also inhibit the release of further noradrenaline by a 
presynaptic agonist effect. Thus, central maintenance of blood 
pressure is impaired and the haemodynamic result is a fall in both 
peripheral vascular resistance and cardiac output (176).
Clinical Features
In common with other centrally acting drugs, a-methyl dopa causes 
sedation. Peripheral effects include hypotension and occasional 
haematological or hepatic disturbances due to autoimmune mechanisms 
A positive Coombs test is common but not a reason to discontinue 
treatment.
Conclusions
Despite the side effects seen with a-methyl dopa, it is a useful 
adjunct to the other drug groups and still is the mainstay of 
treatment of hypertension in pregnancy.
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Angiotensin Converting Enzyme Inhibitors
This is an important new group of drugs with a novel mechanism of 
action. As the subject of this thesis, perindopril, is one of these 
drugs, the clinical pharmacology of the group will be discussed in 
greater detail in the next section.
General Conclusions Regarding Antihypertensive Treatment
From the foregoing discussion of the treatment of hypertension, two 
main conclusions can be drawn. The first concerns the decision on 
whether or not to treat certain groups of patients with drugs.
It is clear that the risk of stroke and cardiovascular disease 
extends down to 'mild' hypertensives, who have a diastolic blood 
pressure of over 90 mmHg. It is also clear that if these patients 
are treated, then only a very small proportion of them will accrue 
any benefit; yet a sizeable percentage of them will suffer side 
effects. Most of these side effects are temporary and will resolve 
on withdrawal of the drug. Many cause symptoms and will ensure that 
treatment will continue only when the treatment is well tolerated. 
Some drugs, however, carry the risk of biochemical toxicity which may 
go unrecognised or ignored. Although the major hypertension trials 
have reported follow-up periods of several years,, there is no 
satisfactory evidence about the risk to benefit ratio of very long 
term treatment and yet this is the logical result of a decision to 
treat young or middle aged mild hypertensive patients. The clinician 
must balance in his mind the relative weights of evidence. The crux
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of this point is that the safer and more acceptable is the available 
treatment, the easier is the decision to exhibit that treatment.
The second conclusion concerns the currently available 
antihypertensive drugs. None is free from side effects and Ehrlich’s 
concept of a 'magic bullet' remains an abstract dream. Present 
treatment is, nevertheless, vastly better than the drugs available at 
the time of the first trial of antihypertensive therapy. The 
preceding discussion of the groups of drugs highlights the differing 
features of each group but it also emphasises that within the groups 
are drugs which have disparate characteristics. It is reasonable to 
conclude that novel compounds will be discovered in the future which 
will further augment the armoury of the physician. It is also 
reasonable that research on new members of the recognised groups of 
antihypertensive agent should proceed. Each improvement in treatment 
which ensues is merely a small step but it does represent progress.
1.3 ANGIOTENSIN CONVERTING ENZYME INHIBITORS
A case has been argued for the development of new antihypertensive 
compounds. The investigation of such drugs is most likely to prove 
worthwhile where a novel mechanism of action is involved or where 
existing members of a drug group are few in number. This thesis 
concerns the early clinical development of one new compound in a 
relatively recent group of drugs, the angiotensin converting enzyme 
inhibitors. At present, only two compounds in this group are 
available for routine clinical use in the United Kingdom. Brief
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mention has already been made of their novel mechanism of action. 
Understanding of the effects of these drugs requires some background 
information on the physiology of the renin-angiotensin system. This 
homeostatic system is therefore reviewed before the history and 
clinical pharmacology of the angiotensin converting enzyme inhibitors 
is described.
Physiology of the Renin-Angiotensin System
The hydrolysis of angiotensinogen to form angiotensin I is catalysed 
by an enzyme, renin, in the blood. This forms the first step in the 
release of angiotensin II from its precursor o^-globulin. Thereafter, 
the carboxyl terminal dipeptide is rapidly cleaved by angiotensin 
converting enzyme to yield the octapeptide, angiotensin II.
Renin
Renin is an acid protease with a molecular weight in its active form 
of about 40,000. It is fairly species-specific. Although originally 
thought to be localised to the kidney and plasma, renin activity has 
now been demonstrated in many other organs including salivary glands 
(39), the reproductive system (192), brain (66), blood vessels and 
adrenals (174). The enzyme is stored in intracellular granules until 
release. In the kidney, the renin-rich cells are modified 
endothelial cells of the afferent glomerular arterioles, which lie in 
close approximation to the macula densa of the distal convoluted 
tubule and which together form the juxtaglomerular apparatus (77).
This apparatus is sensitive to a reduction in the blood pressure and
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salt concentration which it perceives. It responds by releasing 
renin in to the circulation (46). The enzyme which is released is 
not all active. Cold, trypsin and a variety of proteases are capable 
of activating renin (10,48,49,118). Specific inhibitors of renin 
have been elaborated (85) but none is yet available for clinical use.
Angiotensin
The substrate upon which renin acts is a circulating o^-globulin 
which is synthesised by the liver. Although the naturally occurring 
form comprises a series of high molecular weight glycoproteins, it 
appears that only the terminal 14 amino acids are essential to act as 
a substrate for production of angiotensin I (183). Thus, synthetic 
substrates, both active and inhibitory, have been created (56). 
Angiotensin I is a decepeptide which probably has no biological 
activity. One major feature, however, is that it interferes with 
radioimmunoassays for angiotensin II and may cause falsely high 
results, particularly when the ratio of angiotensin I to angiotensin 
II is high.
Angiotensin II is the active octapeptide which remains after 
hydrolysis of the C-terminal dipeptide from angiotensin I. The 
majority of angiotensin II is formed by this route, but alternative 
pathways from angiotensinogen to angiotensin II have been shown to 
exist. One of these relies on the action of another enzyme, tonin, 
and probably obviates the need for angiotensin converting enzyme 
(19).
Angiotensin II has two principal effects in vivo. Firstly, it is a 
potent vasoconstrictor by a direct action on vascular smooth muscle.
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by facilitating peripheral catecholamine release and possibly by 
central actions which increase sympathetic nervous activity.
Secondly, angiotensin II causes salt and water retention by 
stimulating aldosterone release, by a direct effect on tubular sodium 
reabsorption and by central effects which include enhancement of 
thirst, salt appetite and release of antidiuretic hormone and 
adrenocorticotrophic hormone. Angiotensin II is inactivated by 
peptidases, firstly to angiotensin III and then to inactive 
fragments. The biological activity of angiotensin III remains in 
doubt (76).
Angiotensin Converting Enzyme
This is the enzyme responsible for the conversion of angiotensin I to 
angiotensin II. It is a glycoprotein with molecular weight of 
130,000 - 160,000 (184). It is a zinc containing enzyme which is 
activated by chloride and inhibited by metal-chelating agents. It 
acts as an exopeptidase, releasing dipeptides from the carboxyl end 
of a variety of peptides, including angiotensin I, bradykinin, 
enkephalins and substance P (184). Thus, angiotensin converting 
enzyme is also described as kininase II, the main inactivating enzyme 
of bradykinin.
Angiotensin converting enzyme is found circulating in the blood, but 
it is mainly localised to the cell membrane on the luminal side of 
vascular endothelial cells, renal tubular cells and the epithelial 
microvilli of the gut (175). Thus, a significant proportion of its 
substrate is converted across the pulmonary circulation: some 80% of
angiotensin I and 90% of bradykinin is dealt with in a single passage 
of the lungs (158). The lung only accounts for about 45% of
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angiotensin I conversion to angiotensin II, however, since other 
tissues have access to angiotensin I before it reaches the lung (38). 
It is apparent that not only is angiotensin converting enzyme closely 
involved in the production of angiotensin II, it also is responsible 
for inactivating bradykinin. Some description of the kallikrein- 
kinin system is therefore relevant.
The protease enzyme, kallikrein, is found in a distribution analagous 
to that for renin. It catalyses conversion of a kininogen, which in 
contrast to angiotensinogen has low molecular weight, to lysyl- 
bradykinin. This hormone is inactivated by further peptide 
hydrolysis, angiotensin converting enzyme being one of the 
participating kininases. Bradykinin causes potent vasodilatation, 
natriuresis and diuresis. Its circulating levels are not 
consistently altered by inhibition of angiotensin converting enzyme 
and therefore it is not yet clear to what extent the kallikrein-kinin 
system contributes to the effects of the angiotensin converting 
enzyme inhibitors. Nevertheless, it is possible that local changes 
in bradykinin levels occur which are not reflected in circulating 
levels but which are sufficient to cause haemodynamic effects.
Manipulation of the renin-angiotensin system has fascinated 
hypertension workers and physiologists for many years. Goldblatt 
demonstrated in a series of elegant experiments the effects of renal 
ischaemia on the blood pressure (74) and inhibitors of renin are 
still being studied. The aldosterone antagonist, spironolactone, is 
useful in the treatment of hyperaldosteronism. The only drugs with 
more general applicability which specifically modulate the 
renin-angiotensin system and which are clinically available are the
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inhibitors of angiotensin converting enzyme. The history and 
clinical pharmacology of this group will be reviewed in more detail.
Clinical Pharmacology of Captopril and Enalapril 
History
When Ferreira identified a bradykinin potentiating factor derived 
from the venom of Bothrops jararaca in 1965 (58), it was still not 
recognised that angiotensin converting enzyme and kininase II were 
the same enzyme. In 1968, Bakhle confirmed that bradykinin 
potentiating factor also inhibited angiotensin converting enzyme 
(13). It was 1970 before Yang published work concluding that they 
were the same enzyme (224). Bradykinin potentiating factor was 
subsequently purified and identified as a series of peptides which 
could be synthesised (157).
Whilst one of these peptides, teprotide, was very effective as an 
antihypertensive agent (68), it suffered the disadvantages of its 
peptide structure; it was not orally active, it had a short duration 
of action and it was expensive to synthesise. Nevertheless, the 
structure activity relationships which were established from 
teprotide and its congeners together with detailed knowledge of the 
structure of angiotensin converting enzyme allowed synthesis of 
further series of compounds with suitable inhibitory effects (156).
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Chemistry
The two compounds which have been marketed in Britain at this time 
show structural dissimilarity; captopril is a mercaptoacyl amino 
acid whereas enalapril is a carboxyalkyl dipeptide (Figure 1). 
Enalapril is the ester of the more active compound, enalaprilat.
Mode of Action
Current knowledge of the physiology of the renin-angiotensin sytem 
and of the kallikrein-kinin system suggests two main mechanisms by 
which the angiotensin converting enzyme inhibitors may lower blood 
pressure. A reduction in circulating angiotensin levels may lead to 
loss of direct and indirect vasoconstriction. A rise in bradykinin 
levels due to diminished catabolism might cause vasodilatation.
No rise in systemic levels of bradykinin has been reported, but it 
has been postulated that local increases in levels of this hormone 
may still occur and may be responsible for a fall in total peripheral 
resistance (107). Animal work with anti-kinin antibody has 
demonstrated that the antibody can prevent the fall in blood pressure 
associated with captopril given to rats with renovascular 
hypertension but does not affect the hypotensive action of captopril 
given to salt-depleted animals (29). Captopril could not be 
demonstrated to enhance the effect of bradykinin infusion locally to 
the kidney (59).
There is evidence of a relationship between bradykinin and 
prostaglandin E^ release (148). Angiotensin converting enzyme 
inhibition does increase prostaglandin E^ production in 
renomedullary interstitial cells (226). Captopril has been shown to
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augment prostaglandin production in hypertensive man and
indomethacin, which is an inhibitor of cyclo-oxygenase, can prevent 
the hypotensive action of captopril (191). Indomethacin also 
antagonises other antihypertensive drugs, however (55,173,212). 
Further, angiotensin II infusion has also been shown to augment 
prostaglandin release (138). Thus, the role of bradykinin in 
the mechanism of hypotension after angiotensin converting enzyme 
inhibitors is still a matter for debate.
As regards the renin-angiotensin system, investigators have variously 
reported that the antihypertensive effects of the angiotensin 
converting enzyme inhibitors are closely correlated (7,31,42), 
sometimes correlated (21) and not related (131) to the plasma renin 
activity before dosing. A degree of salt or volume depletion is 
necessary for the blood pressure lowering effect when plasma renin 
activity is not high, however (33,131). The angiotensin converting 
enzyme inhibitors do lower angiotensin II concentrations (24,100). 
Thus, a reduction in both direct and sympathetically mediated 
vasoconstriction occurs (37,198). The modulation of the sympathetic 
neural effects appears to occur even with low initial levels of 
angiotensin II (108), which helps to explain why anephric patients 
may still respond to angiotensin converting enzyme inhibitors (131). 
Angiotensin II levels may regulate the number of angiotensin II 
receptors (84) and, therefore, the effects of angiotensin converting 
enzyme inhibitors might reasonably be expected to occur, regardless 
of the plasma renin activity.
Since neither captopril (125) nor enalapril (96) consistently lowers 
aldosterone after long term treatment, it seems unlikely that effects
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on aldosterone are responsible for the long term antihypertensive 
action.
Circulating catecholamines have been shown to fall (215), to be 
unchanged (136,153) and, in certain instances, to increase (146) after 
angiotensin converting enzyme inhibition. Since an enhanced response 
to catecholamines (91) and possibly increased resting levels (34) 
have been implicated in essential hypertension, an interaction 
between angiotensin converting enzyme inhibitors and the sympathetic 
nervous system via angiotensin II could conceivably explain the 
hypotensive action of these drugs.
One area of particular interest has been the effect of the 
angiotensin converting enzyme inhibitors on heart rate control. It 
is well established that vasodilatation occurs with these drugs, but 
that the reflex tachycardia which is seen with many vasodilators does 
not occur (61,102,143,193) though the response to tilt (14) and 
exercise (132) is unaffected. Clearly, this could be due to removal 
of angiotensin II mediated facilitatory effects on the sympathetic 
nervous system; yet the evidence suggests that parasympathetic 
rather than sympathetic mechanisms may be responsible for the 
tachycardia after other vasodilators (130). Saralasin, the 
angiotensin II partial agonist, reduces heart rate in dogs and this 
effect can be abolished with atropine (20). Captopril caused 
enhancement of bradycardia in the diving reflex test in hypertensive 
patients (188). Finally, central effects of angiotensin II on heart 
rate seem to be mediated by the vagus nerves (177). Interestingly, 
the central effects of angiotensin II on blood pressure are also 
abolished by atropine (177) and by ablation of the area postrema in
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dogs (110) .
Absorption, Metabolism, Excretion
Initial studies of the pharmacokinetics of captopril were confounded 
by the instability of the drug in vitro (172). Published reports 
must therefore be treated with caution. Studies using radiolabelled 
compound have yielded some information, however.
Captopril is rapidly absorbed after oral administration, reaching 
peak blood levels in one hour, and has oral bioavailability of 62%.
-I
The volume of distribution at steady state is 0.7 l.kg and the 
elimination half life is 1.7 - 1.9 hours (53). Three-quarters of an 
oral dose is excreted in the urine, 58% in an unchanged form, 40% as 
polar metabolites and 2% as disulphide (114). Elimination is reduced 
in renal failure (171) and by coadministration of probenecid.
Tubular secretion is thus important (182).
Enalaprilat is poorly absorbed, but absorption of its esterified 
form, enalapril, exceeds 60% and over 70% of enalapril which is 
absorbed is hydrolysed to the active metabolite (203), probably in 
the liver (200). Peak blood levels of enalaprilat are achieved 
within four hours of administration (17,143). Urinary recovery of 
enalapril and enalaprilat together accounts for 61% of the 
administered dose, and faecal recovery offers a further 33% (203). 
Reduced clearance in the elderly has been shown to correlate with 
diminished creatinine clearance (94).
The kinetic profile of enalaprilat is polyphasic, with a long 
terminal phase (94,203) but, despite an apparent terminal
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half-life of 35 - 38 hours (94,203), Till al (197) estimate 
the accumulation half-life to be only 11 hours. This has led to 
controversy over the relevance of standard pharmacokinetic models to 
the description of the disposition of enalaprilat. It has been 
suggested that protein binding of enalaprilat occurs and that, as a 
result, a small pool of drug is excreted very slowly.
Efficacy
Both captopril and enalapril are of proven benefit in several forms 
of hypertension and in congestive heart failure. They may be used in 
renovascular hypertension (25,95,96) and may predict the response to
surgery (9). Caution is necessary, however, since renal function
may deteriorate if the only functioning renal tissue is distal to a 
stenosis (99). Fortunately, the change in renal function is usually 
reversible. It has also been suggested that captopril may be a
diagnostic aid in renal artery stenosis: it causes a greater rise of
plasma renin activity in renal artery stenosis than in essential 
hypertension (30) and causes exaggeration of the asymmetry seen in 
functional renal isotope scans vÈien unilateral renal artery stenosis 
is present (216).
These drugs have been used successfully in the treatment of severe 
and malignant hypertension (32,51). They are effective in primary 
hyperaldosteronism without tumour (82,133), possibly because this 
condition is due to increased adrenal sensitivity to angiotensin II 
(222).
Of greater importance numerically are the patients with essential 
hypertension. Many reports are now available showing benefit with
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either captopril or enalapril in these patients (67,208,209). These 
studies have used twice daily administration of captopril, but 
comparison of once daily and twice daily administration with 
enalapril has shown equal benefit with the single daily dose (16). 
Coadministration of a diuretic is often required to achieve an 
optimal effect in patients with essential hypertension.
The value of angiotensin converting enzyme inhibitors in congestive 
heart failure is now fairly well recognised (36,202). Cardiac output 
rises while blood pressure, total peripheral resistance, right atrial 
pressure, pulmonary artery pressure and pulmonary wedge pressure are 
lowered (112,122). The fall in blood pressure may sometimes be 
profound, but it has been suggested that this is usually well 
tolerated because of a simultaneous increase in cerebral blood flow 
(105). The mechanism of the falls in afterload and preload are not 
clear: removal of a direct action of angiotensin II is unlikely,
since angiotensin II does not directly affect the venous system (159) 
and since rebound rises in angiotensin II levels after withdrawal of 
captopril do not cause arterial vasoconstriction (152). Significant 
subjective and objective improvements in exercise tolerance have been 
reported after angiotensin converting enzyme inhibitors and there has 
been a suggestion that survival is improved (113). A reduction in 
complex ventricular arrhythmias has been noted (36).
Clinical Features
The reported side effects with captopril must be assessed with care. 
The initial studies with captopril in patients concentrated on the 
treatment of unusual or high risk disease. Full clinical 
pharmacology was not known at the time and certain errors were made
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in dosing which were avoided when enalapril became available. Thus, 
a comparison of the incidence of side effects with the two drugs 
must allow for major differences in the populations at risk.
The side effects commonly encountered with the angiotensin converting 
enzyme inhibitors are rash, taste disturbance, headache, lassitude, 
hypotension, proteinuria and neutropenia. The respective incidences 
of these complications for captopril are 6%, 3.1%, 2.9%, 2.7%, 2.5%, 
0.6%, and 0.04% and for enalapril are 1.5%, 0.5%, 5.6%, 5.1%, 2.4%, 
1.4% and 0.06% (187). The at-risk group for captopril in the above 
report comprised nearly 5000 patients of whom over 90% had moderate 
to severe or renovascular forms of hypertension, whereas the 2000 
patients given enalapril included only 18% such 'high risk' patients. 
That this is relevant is evidenced by the strikingly higher incidence 
of haematological side-effects with captopril in patients with 
collagen disease and renal failure together (7.2%) compared with 
patients having renal failure alone (0.4%) or normal renal function 
(0.02%). Since captopril is renally excreted (89) and most of the 
side effects are now known to be dose-related (208) it may be that 
the differences between the two drugs are not so great as once was 
thought. This point is disputed by the manufacturers of enalapril, 
however (75,144).
Both rash and taste disturbance are usually dose-related. Cough and 
angioneurotic oedema may occur with either drug (106). Proteinuria 
occurs with both drugs in similar numbers of patients. The 
nephropathy was originally attributed to the sulphydryl group in 
captopril, and some supporting biochemical work was published (103). 
The similar incidence with enalapril and the relatively low incidence
54
with both drugs in contrast to the incidence seen with penicillamine, 
which causes proteinuria in 20% of patients treated, argue against 
this mechanism and have led to greater tolerance of captopril by 
physicians in recent years.
On the positive side, the combination of an angiotensin converting 
enzyme inhibitor with a thiazide diuretic has been reported to reduce 
the incidence of some of the biochemical side effects of the diuretic 
(214). An additional feature of the angiotensin converting enzyme 
inhibitors is that they lower blood pressure without causing reflex 
sympathetic activation (44) and are, therefore, particularly useful 
in the treatment of hypertension complicating angina, although a 
^-blocker would normally remain first line treatment.
Finally, there have inevitably been some reports of unusual illnesses 
during captopril treatment (8,163). These cannot be confidently 
attributed to the drug at present.
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1.5 INITIAL INVESTIGATION OF NEW DRUGS IN MAN
The rationale for investigating a new antihypertensive agent has been 
set out above. When the studies of the clinical pharmacology of 
perindopril (Chapters 3 to 8) were planned, limited information was 
available concerning administration of the drug to man. It is 
therefore relevant to disuss the procedures involved in the initial 
stages of the clinical investigation of a new drug.
Introduction
The development of a new drug follows a fairly standard path. After 
synthesis or discovery of the new compound, it is tested vitro and 
in animal experiments for particular pharmacological properties. If 
it possesses useful activity, it is then subjected to rigorous 
examination of its pharmacokinetic properties and toxicology in 
animals. Only if it continues to show promise does it continue 
beyond this preclinical stage.
The clinical stages have been classified into four phases; phase 1 
covers the first administration to man, usually healthy volunteers, 
and assessment of disposition and tolerance; phase 2 extends the 
earlier work to establish early evidence of efficacy, appropriate 
dosage and further assessment of safety; phase 3 permits the 
detailed examination of efficacy and comparison with any established 
treatment, along with further assessment of safety; phase 4 covers
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the period after marketing when efficacy has been accepted but 
surveillance for safety in large numbers of patients is necessary.
In contrast to the extensive literature on the subject of controlled 
clinical trials of drugs during phase 3 of their development, there 
is little on the subject of initial studies of a new compound.
Several points may be considered.
Firstly, whilst it has been advocated that administration to humans 
should be a very early step in the development of a new drug (189), 
albeit under strictly controlled conditions, there is general 
agreement that adequate pharmacological and toxicological data should 
first be obtained in animals (22,52,70,73,79,117,204). The second 
point is that no strict criteria may be laid down for the conduct of 
such studies; the potential toxicity or efficacy of the compound 
dictates the manner in which these are approached. Thirdly, as a 
corollary to the latter point, the aims of such studies vary between 
compounds. Fourthly, some discussion should be devoted as to who 
should conduct early studies in man. Finally, certain ethical and 
legal considerations pertain to the conduct of these investigations. 
These points will be dealt with in the following paragraphs.
Legal Requirements
The restrictions upon administration of novel compounds to man and 
the requirements for documenting the early studies to allow for 
future licensing of the drugs vary from one country to another. For 
example, France does not in theory permit the conduct of studies in 
normal volunteers, the USA has a long tradition of recruiting 
volunteers from prison inmates and Britain has at present no
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restriction on administration of unlicenced compounds to normal 
volunteers, yet it does exert strict control over administration to 
patients. Likewise, the American Food and Drug Administration 
differs in its requirements before licensing from the United 
Kingdom's licensing authority. The regulations discussed hereafter 
are restricted to those of Great Britain and Northern Ireland.
In the decade from 1971 to 1981, there was a deal of discussion and
criticism of the onerous requirements to be met before a drug could 
be tested in patients (22,41,69,70). There was evidence that British 
companies were sending their new discoveries abroad to be tested and 
that clinical pharmacologists in this country were not gaining 
necessary experience in the early clinical trials (80). Part of the 
blame for this was attributed to the delay which occurred, after 
pre-clinical work had been completed, before a clinical trial
certificate was granted. Thus, in 1981, new regulations came in to
force (98).
The essence of these regulations was that they expanded a loophole in 
the Medicines Act 1968. Following an amendment to that Act in 1972, 
it had been possible for a clinician acting on his own initiative to 
apply for exemption from holding a clinical trials certificate for a 
particular compound (97). This was ordinarily granted after only 
'negative vetting' of the information about the drug under 
consideration. This contrasts with the 'positive vetting' of the 
detailed pharmacological and toxicological data demanded of the 
pharmaceutical industry before granting a Clinical Trials 
Certificate. The detailed vetting is normally carried out on behalf 
of the licensing authority (i.e. the Secretary of State attached to
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the Department of Health and Social Security, through the Medicines 
Division of that Department) by the Committee on Safety of Medicines
Thus, since 1981, the pharmaceutical companies have still been 
required to generate the same basic data to support the proposed 
study. They have been required to send to the licensing authority 
only certified summaries of these and other relevant data, however, 
together with a copy of the protocol and a supporting letter from a 
medical adviser to the company, working in the United Kingdom.
The licensing authority has 35 days in which to consider the 
application, with an option of a 28 day extension. If granted, the 
onus is placed upon the exemption holder to report any change in the 
protocol, any adverse reaction to the drug, any other information 
casting doubt on safety and any refusal by an ethical committee to 
approve the trial.
Griffin has clarified the position of ethical committees in this 
respect (81). There is no extra responsibility in the case of 
Exempted Trials; they continue to consider the ethics of the trial 
as a whole.
The reported increase in the number of early clinical trials being 
conducted under the revised procedures and the absence of evidence 
suggesting any change in the adverse event rate attest to the value 
of the revised procedures (185).
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Ethical Considerations
A full discussion of the ethical considerations involved in the early 
clinical trials of a new drug is outwith the scope of this review. 
Certain guidelines have evolved, however, which are compatible with 
the Declaration of Helsinki. The project and protocols must be 
approved by a local ethical committee. Informed consent must be 
voluntarily given, in writing, and independently witnessed. Written 
information on the purpose of the study, the procedures, risks and 
discomfort anticipated should be provided. It must be clear to the 
volunteer or patient that he may withdraw from the study at any stage 
and without prejudice to his medical care.
Subjects
The choice of subjects for phase 1 and 2 studies depends on several 
factors. The nature of the drug to be tested is the first of these. 
There is agreement that anti-cancer drugs, because of their low 
therapeutic index, should be tested only in patients with that 
disease (52,127) and that certain compounds can only be tested for 
an effect in patients with the relevant condition. Dollery cites as 
an example the use of L-dopa for Parkinsonism (52). For drugs with 
a safety profile which is thought to be good and in studies where 
assessments of safety, tolerance and clinical pharmacology rather 
than of therapeutic efficacy are the aims, there are good arguments 
for recruiting normal volunteers. These subjects provide a stable 
milieu in which detected changes are likely to be drug induced.
There will be less variation in response and therefore more 
confidence in the results. A caveat to the sole use of 'normal 
healthy volunteers' is that further studies may be required to show 
the relevance of early data to heterogeneous groups, such as the
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elderly (205).
The source of normal volunteers has vexed some minds in the past 
(12) as have the criteria for their selection (109). A good case 
exists for restricting recruitment from the staff of a company which 
will subsequently market a drug, on the grounds that undue pressure 
on the 'volunteer* cannot be excluded. Prison inmates may be 
similarly placed, though Ayd argues otherwise (12). Recruitment 
amongst staff in an independent department of clinical pharmacology 
probably avoids the problem of undue pressure and also ensures some 
prior knowledge of risks and procedures involved. Laurence writes 
that he favours the situation where investigators frequently 'renew 
the experience of being an experimental subject' (117).
Investigator
This leads to the choice of clinical investigator. The views of 
clinical pharmacologists are in accord on this subject: an
independent clinical pharmacologist with appropriate training and 
experience, working in a well equipped and staffed laboratory within 
a hospital should be responsible for the first administration of a 
new compound to man (52,73,117,204). Subsequent trials of efficacy 
in patients may be carried out by clinical specialists. There is of 
course scope for flexibility between these stages.
Aims of Early Studies
George (69) has described the purpose of clinical studies as 
threefold: 'firstly, to establish that the drug has a useful action
in man; secondly, to confirm that it is non-toxic; and, thirdly, to 
establish the nature of common side effects'. In practical terms.
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however, early studies cannot answer these questions adequately. For 
example, serious toxic effects may have an incidence of one in 10,000 
or lower and so will be unlikely to occur during early studies (23). 
The aims of phase 1 studies have therefore been simplified to 
assessment of the following (204):
1) human tolerability of the compound
2) pharmacokinetic behaviour and metabolism of the new 
investigational drug
3) effects of the compound on physiological functions
4) preferred route of administration
5) safe dosage range
The aims of phase 2 studies will also attempt to consider:
1) efficacy
2) optimal dosage range
3) side-effects and toxicity
4) choice of pharmaceutical formulation
5) mechanism of action
Inevitably, it is not possible to assess more than one or two points 
in a single study. Not all of these will be relevant for all new 
drugs, however: route of administration and formulation may have
been decided beforehand; mechanism of action may be clear from 
pre-clinical pharmacology. Since it is clearly inappropriate to 
assess tolerability at a subtherapeutic dose, and since neither 
therapeutic dose nor safe dosage range have been established until 
phase 1 studies have been completed, the first practical step must be 
to perform a dose-ranging study.
Goldberg et al (73) suggest that the starting dose should be
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considerably below the minimum effective dose in animals and that 
logarithmic increments in dose are sensible; they freely admit, 
however, that the choice of dose and of increment is arbitrary. They 
recommend a minimum of three subjects be given each dose. Various 
authors reach a firm consensus on one point; no firm guidelines can 
be laid down for a standard phase 1 study of any drug (52,69,73,117, 
204). Each compound must be considered on its merits and in the 
light of the available pre-clinical data, likely safety profile, etc.
Finally, phase 3 studies should aim to demonstrate efficacy and 
superiority over existing treatments; the comparison should include 
safety, efficacy, acceptability and probably cost. Proof of equality 
is probably insufficient to justify marketing though this is not yet 
a widely accepted point.
Pre-clinical data
No attempt will be made to list the necessary pre-clinical data on a 
new drug, nor to review the methods of obtaining or assessing such 
data. In general terms, however, the information should cover three 
topics (117,204):
1) the action, efficacy and mechanism of the drug - the 
pharmacodynamics
2) absorption, metabolism and excretion - the pharmacokinetics
3) animal toxicology
Conclusions
From the preceding discussion, it should be clear that the 
development plan for a new drug through the early clinical stages is 
heavily dependent on the preclinical data for that compound and on
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any available information concerning the effects of similar drugs in 
man. The aims of the early studies have been identified. An outline 
of the regulations and the consensus view on conduct of such 
investigations has been presented.
1.5 SCOPE OF THESIS
The study of the clinical pharmacology of the drug which forms the 
subject of this thesis, perindopril, offers a specific example of the 
application of many of the above points. The preclinical data for 
perindopril are summarised in Appendix 1. Some of the animal 
pharmacology has now been published (50,116). Limited information 
was available, in the form of unpublished work from the manufacturers 
(Institut de Recherches Internationales Servier), who had 
administered single doses of perindopril orally to pairs of 
volunteers up to 16 mg without obvious side effects or toxicity.
The studies on perindopril which follow were designed in the light of 
the safety profile in animals and of the knowledge which is now 
available regarding captopril, a drug with a similar pharmacological 
profile to perindopril, but more particularly based on experience 
with enalapril, a drug with similar pharmacology and structure to 
perindopril.
It was necessary not only to have means of measuring drug action 
(blood pressure, heart rate, plasma angiotensin converting enzyme 
activity and hormones) but also to develop a new assay for the 
metabolite of perindopril in plasma (Chapter 2).
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The first series of studies, involving some of the earliest 
administrations of perindopril to man, established the dose-response 
relationship of single and multiple doses in normal subjects 
(Chapter 3). The first ever administration to man of the active 
metabolite, S-9780, is described in Chapter 4. Chapter 5 covers the 
interaction of perindopril with the autonomic nervous system in 
normal subjects. Early phase 2 studies in essential hypertension 
permitted the evaluation of the dose range predicted from the earlier 
studies and confirmed antihypertensive efficacy and good tolerance 
(Chapter 6).
Finally, in Chapters 7 and 8, the pharmacokinetics of the drug and 
the concentration-effect relationships are examined using a novel 
approach to permit an integrated overview of the actions of this new 
drug in man.
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CHAPTER 2
66
LABORATORY METHODS
2.1 PLASMA ANGIOTENSIN CONVERTING ENZYME ACTIVITY
Plasma angiotensin converting enzyme activity was assayed by 
measuring the rate of generation of hippuric acid in an incubation 
mixture containing plasma and hippuryl-histidyl-leucine (A3).
Hippuric acid was measured by high pressure liquid chromatography as 
described by Chiknas (35).
Reagents and Materials
Hippuryl-L-histidyl-L-leucine, hippuric acid and phthalic acid were 
obtained from Sigma Chemical Company Limited, Dorset. All other 
reagents were ’A.R.’ grade as supplied by Fisons Limited, England.
Chromatography
A Hewlett Packard 108AB with a Hewlett Packard 79850B LC terminal was
used, with a Hichrom Spherisorb 5 /urn CDS column (12.5 cm x A mm ID).
The detector was a Pye Unicam LC3 UV detector set at 228 nm. The
_ 1
mobile phase used was 20 mM KH^PO^, pH 4.6 : methanol 40 ml.l
-1
at a flow rate of 2 ml.min 
Sample Requirements
At least 100 /ul of plasma or serum are required for angiotensin 
converting enzyme analysis. It has been shown that there is no 
significant difference between plasma and serum angiotensin
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converting enzyme activity. Samples collected in EDTA are unsuitable 
for angiotensin converting enzyme analysis as EDTA has been found 
almost completely to inhibit the enzyme.
Samples from patients taking no angiotensin converting enzyme 
inhibitor can be stored for up to 6 months at -20°C without any 
appreciable decrease in enzyme activity.
It was found that the angiotensin converting enzyme activity of 
haemolysed samples was decreased by up to 50%.
Methodology and Standards 
Standard Solutions
A standard curve for hippuric acid was constructed by spiking the 
plasma of a normal volunteer with varying amounts of hippuric acid 
(0.05 - 0.5 mmol.l” )^. These standards could be kept at -20°C for 
at least 2 months, with frequent defrosting and refreezing having no 
effect.
Internal Standard (IS)
Phthalic acid for use as an internal standard was used at a 
concentration of 200 ^ M. This could be stored at 4 C for at 
least 2 months without significant degradation occurring.
Substrate
Five mmol of hippuryl-L-histidyl-L-leucine were dissolved in substrate 
buffer. This was made up freshly for each assay as there is a 
gradual increase in free hippuric acid with storage. The substrate 
buffer was 100 mM potassium phosphate buffer pH 8.3 containing
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300 mmol NaCl per litre.
Method
Standards and unknown samples were assayed slightly differently: 
Plasma standards in duplicate
400 jul substrate buffer containing no Hip.His.Leu 
+ 40 /llI 50% HCl vortex
+ 20 jul standard plasma vortex
+ 40 lul IS vortex
+ 10 mg (approx) NaCl vortex
+ 800 jul ethyl acetate vortex for 15 seconds
Unknown samples in duplicate
400 jul substrate buffer containing Hip.His.Leu
+ 20 ^1 unknown plasma
+ 40 lul 50% HCl
+ 40 ^1 IS
+ 10 mg (approx) NaCl
+ 800 ^1 ethyl acetate
vortex
incubate at 37°C for 15 minutes
vortex
vortex
vortex
vortex for 15 seconds
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Plasma standards and unknown samples, continue as follows:
Centrifuge for 5 minutes at 2000 rpm 
Remove 400 fjl organic layer to clean tube 
Concentrate under N^/air at 37°C 
Reconstitute in 100 ^1 mobile phase 
Inject aliquot into HPLC system
Calculation of Angiotensin Converting Enzyme Activity
Results were calculated using peak area. The peak area ratio for
hippuric acid/IS was plotted against hippuric acid concentration.
The hippuric acid/IS ratio for the unknown sample was then read off 
the graph, giving a value in mmol of hippuric acid per litre generated 
in 15 minutes. One unit of angiotensin converting enzyme activity is 
that which converts 1 ^mol of angiotensin I to angiotensin II per 
minute.
Sensitivity and Reproducibility
Inter and intra assay coefficients of variation were 6.1% and 2.3% 
respectively and the limit of detection was 0.5 EU.l . Samples 
were assayed within four weeks of collection.
Normal range
The normal range for the laboratory was 15.3 - 26.9 EU.ml  ^ (95% 
confidence interval).
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2.2 PLASMA RENIN ACTIVITY
Plasma renin activity was determined by a specific radioimmunoassay 
of angiotensin I formed upon cleavage by renin of its substrate
angiotensinogen (49). The limit of detection of the assay was
- 1 - 1  
1 ngAI.ml .hr and t
and 5.5% respectively.
1 - 1
he inter and intra assay variations were 7.0%
2.3 PLASMA ALDOSTERONE
Plasma aldosterone concentrations were measured by a direct 
radioimmunoassay using the method of McKenzie ^  ^  (139). The 
limit of the assay was 10 pg.ml  ^and the inter and intra assay 
coefficients of variation were 11.0% and 7.3% respectively.
2.4 PLASMA CATECHOLAMINES
Adrenaline and noradrenaline concentrations in plasma were determined 
by a radioenzymatic assay based on the method of da Prada and Zurcher 
(167). The method is dependent upon the determination of the méthyl­
ation of the catecholamines with tritiated s-adenosyl methionine by 
the action of purified catechol-o-methyl transferase. The limit of 
detection for noradrenaline was 0.1 nmol.l  ^ and for adrenaline was 
0.03 nmol.l"''. The inter and intra assay variations were respectively 
15% and 13% for noradrenaline and 20% and 15% for adrenaline.
71
2.5 PLASMA S-9780 CONCENTRATIONS
Plasma S-9780 concentrations in plasma were estimated by an enzyme- 
inhibition assay based on the method of Tocco ^  ^  (200). The 
assay was developed in the laboratories of the Department of Materia 
Medica. The diacid metabolite of perindopril, S-9780, was separated 
from plasma using an ion exchange column. Subsequent analysis of 
metabolite concentration depended upon the degree of inhibition of a 
standardised angiotensin converting enzyme preparation using high 
pressure liquid chromatography to detect the product of the reaction.
Methodology and standards
Five hundred ^1 of plasma was adjusted to pH 2 by the addition of 
50 iLil of 0.1 M hydrochloric acid. This was then poured on to an 
XAD-4 column and the tube was rinsed twice with 2 ml of 0.1 M HCl, 
the rinses being added to the column. The column was then washed 
with a further 6 ml of 0.1 M HCl added slowly in 3 aliquots. The 
sample was eluted from the column with 3 x 1 ml methanol and the 
methanol was then reduced to dryness under a stream of nitrogen at 
45°C. The samples were reconstituted with 0.2 ml methanol and 
0.8 ml of angiotensin converting enzyme buffer (phosphate buffer 
0.5 M, pH 8.3, and 0.6 M NaCl).
The HPLC assay of Chiknas et ^  (35) was then employed to determine 
the inhibition of a standardised preparation of angiotensin 
converting enzyme. One hundred fii. of reconstituted eluant were added
72
to 400 fil of substrate (hippuryl-histidyl-leucine). Substrate 
concentration in the assay system (5 mM) was such that more than 
80% remained unchanged after the incubation with the enzyme. Fifty 
fil of diluted rabbit plasma were added such as to give a final 
dilution of 1 in 33 of the rabbit plasma in the enzyme assay system.
Samples were then incubated for 15 minutes at 37*^ C, the reaction 
being stopped with 0.1 ml of 6 M HCl. Internal standard was added 
(15 fil of 0.1 mM o-phthalic acid), followed by approximately 10 mg of 
NaCl and 0.8 ml of ethyl acetate. After mixing, the samples were 
centrifuged and 0.5 ml of supernatant were evaporated to dryness 
under nitrogen at 60°C. This was then reconstituted with 0.1 ml of 
HPLC mobile phase (60% 0.02 M phosphate buffer pH 8.0 and 
40% methanol) and 25 fil of this was injected into the chromatograph. 
Separation was effected on a 25 cm 5 fim CDS spherisorb column at a 
flow rate of 2 ml.min .
Hippuric acid generated by the action of rabbit plasma angiotensin 
converting enzyme was detected at 228 nM and was related to the 
internal standard by peak height ratios. Each batch of samples was 
assayed along with a series of standard callibrators 
( 0 - 2 5  ng.ml"^) along with two quality control standards. The 
standard curve was constructed by plotting the peak height ratio of 
each standard against its respective concentration; the unknowns 
were measured by interpolation from the standard curve (Figure 2).
Sensitivity
All samples were assayed in duplicate and results were calculated 
where the inhibition was within the range 15-80%. Samples with
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Figure 2. Typical standard curve for S-9780 assay.
inhibition greater than 80% (< 25 ng.ml  ^) were reanalysed with 1:1 
dilution of the plasma. Inhibition less than 15% was defined as 
being below the limit of sensitivity of the assay, and in the assays 
performed, this was within the range of 0.5 to 1.0 ng.ml"”*.
Specificity
The specificity of the assay was assessed with reference to the 
parent drug compound, perindopril. Plasma samples were spiked with 
1000 ng.ml of perindopril and were run through the assay using 
both rabbit and rat plasma. No inhibition was observed in the final 
enzyme assay step.
Further studies were undertaken to consider the assay specificity, 
however, by incubation of the XAD-4 column eluate with dilute rabbit 
and rat plasma prior to addition of angiotensin converting enzyme 
substrate. It was apparent from this study that with incubation 
times in excess of 6 hours rat plasma induced approximately 20% 
inhibition in the final assay step, indicating conversion of 
perindopril to S-9780. In contrast, no inhibition was observed with 
rabbit plasma. As a consequence, rabbit plasma was used in all 
assays.
Reproducibility
Intra assay variability was assessed by the replicate analysis of 
'spiked' plasma standards both within the normal range of the assay 
and, after dilution, beyond the upper limit of the assay. The 
results are summarised in Table 1.
Inter assay reproducibility was assessed by the use of quality
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Plasma standard mean SD CV
. —  1 —  1 
rg.ml ng.ml %
1 1.1 0.2 16.0 12
5 5.2 0.5 10.4 10
10 9.9 0.7 7.3 10
15 16.3 1.0 6.4 10
20 18.0 1.5 8.4 13
200 189.9 29.2 15.4 13
Table 1. Plasma S-9780 estimation; intra assay precision and 
variability. Samples having concentrations greater than 20 ng.ml ”* 
were assayed after appropriate dilution.
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control standards which were run with each assay, at concentrations
-1 -1 of 4.0 ng.ml and 16.0 ng.ml . The coefficient of variation
for the lower standard was 8.8% and for the upper standard was 4.1%
(n = 29).
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CHAPTER 3
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ORAL DOSE RANGING STUDY WITH PERINDOPRIL
3.1 INTRODUCTION
Perindopril is a new orally active inhibitor of angiotensin 
converting enzyme. It has a non thiol structure (Figure 3) and 
although it is itself relatively inactive, it is rapidly hydrolysed 
in vivo to the active diacid metabolite, S-9780. This compound 
is a potent and long lasting inhibitor of angiotensin converting 
enzyme in animals (116) and in preliminary single dose studies in man 
(Institut de Recherches Internationales Servier: personal 
communication). This chapter describes a study of the tolerance and 
dynamic effects of oral perindopril for 7 days in healthy 
normotensive volunteers.
3.2 METHODS 
Subjects
Thirty six male volunteers were recruited from the staff of Stobhill 
General Hospital. They were screened prior to entry by history, 
general examination, urinalysis, electrocardiograph and routine 
laboratory tests of haematology and serum biochemistry to ensure good 
health. Two further volunteers were rejected, one because of mild 
iron deficiency and the other because he was found to have Gilbert's 
disease. Written informed consent was obtained from all subjects and
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PERINDOPRIL (S 9490 -3 )
CH.
CH3 -C H 2 -C H 2 -H C -N H -C H -C O -N
COOCjH, J
(S 9780)
CH.
CH3-CH2-CH2-HC-NH-CH-CO-N
GOGH YGOGH
Figure 3. Chemical structure of perindopril and of its active 
diacid metabolite, S-9780.
the study design was approved by the local ethical review committee. 
The mean age of the volunteers was 25 years (range 18 - 35), their 
mean weight was 72 kg (range 59 - 92) and their mean height was 176 
cm (range 162 - 188). Full details are given in Table 2(a-c). There 
was no statistical difference between the sub-groups. No salt 
restriction was imposed and although salt status was not measured on 
this occasion, subsequent experience with a group of these subjects 
showed 24 hour urinary sodium excretion to be 226 mmol (range 124 - 
406, n = 8) and 24 hour urinary potassium excretion to be 82 mmol
(range 10 - 141, n = 8).
Study Design
This was an open, dose ranging study in 6 parallel groups; blocked 
randomisation of 12 subjects to either placebo or 8 mg of perindopril 
was carried out, however, and these subjects were studied in double 
blind fashion. The other doses studied were 1, 2, 4 and 16 mg. Each 
dose was administered for seven consecutive days to 6 subjects.
The subjects arrived at the Clinical Pharmacology Research Unit at 
0830 hours on the first study day. They had fasted since 2200 hours
on the previous night and had avoided all drugs for the previous two
weeks. No smoking, caffeine or alcohol ingestion was permitted 
during the study. An indwelling venous cannula was inserted in to an 
antecubital vein and the subjects rested supine until the start of 
the study. Blood pressure and heart rate were measured in duplicate 
by Sentron semiautomatic sphygmomanometer (Bard Biomedical) after 
ten minutes' supine rest and 5 minutes standing before dosing and at 
the following intervals after dosing: 1, 2, 4, 6, 8, 10, 12 and 24
hours. Blood samples were drawn for plasma angiotensin converting
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Dose Subject Age Weight Height
years kg cm
Placebo 20 22 65.9 172
22 26 92.1 178
23 30 71.0 174
24 22 79.8 181
27 27 67.6 162
29 26 74.0 172
mean 26 75.1 173
SD 3 9.7 7
1 mg 5 24 62.7 173
6 18 68.3 183
11 31 71.4 180
12 22 74.1 181
13 34 72.0 167
16 22 88.8 175
mean 25 72.9 176
SD 6 8.8 6
Table 2a. Demographic data for subjects studied after oral 
perindopril. Subject numbers are in order of recruitment and are 
referred to later in the text.
80
Subject Age Weight Height
years kg cm
2 mg 1 22 65.8 176
2 35 62.6 174
3 27 62.0 184
4 22 75.7 176
7 22 69.4 178
8 22 62.0 179
mean 25 66.2 178
SD 5 5.5 3
4 mg 9 26 67.5 172
10 33 85.0 183
14 30 64.5 168
15 28 68.5 173
17 28 67.5 170
18 34 65.5 178
mean 30 69.8 174
SD 3 7.6 6
Table 2b. Demographic data (continued).
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Dose Subject Age Weight Height
years kg cm
8 mg 19 28 72.3 178
21 22 65.8 177
25 21 71.4 168
26 28 71.7 176
28 31 82.4 180
30 22 59.2 167
mean 25 70.5 174
SD 4 7.7 5
16 mg 31 19 79.4 173
32 25 70.0 179
33 21 67.0 178
34 21 77.0 185
35 22 76.0 188
36 23 79.0 188
mean 22 74.7 182
SD 2 5.1 6
Table 2c. Demographic data (continued).
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enzyme activity at the same times as blood pressure was measured. 
Samples were also collected for plasma renin activity, aldosterone, 
adrenaline and noradrenaline levels pre-dosing and after 4, 8 and 24 
hours.
Plasma samples for assay of S-9780, the active diacid metabolite, 
were also collected and are described in Chapter 7.
Capsules containing the appropriate dose of drug or placebo were 
administered orally with 200 ml of water at 0900 hours and the 
subjects remained fasting for a further two hours. A light standard 
meal was provided after 4 hours and 8 hours. Free fluids were 
permitted after 4 hours and after this time the volunteers were no 
longer restricted to bed between recordings.
On the second to sixth days of dosing, the volunteers attended the 
laboratory at 0900 hours and 1500 hours for further blood pressure 
recordings and blood sampling. The drug was administered after the 
0900 sample each day. The results of these recordings are not
reported in this chapter.
On the seventh day of treatment, the protocol for the first day was 
repeated exactly. The volunteers were reviewed 24 and 48 hours after 
this final dose.
The pre-study screening investigations were repeated both during the
week of the study and after completion, the subjects were questioned
about any symptoms at each recording time, and samples for 
angiotensin converting enzyme activity were measured within 1 to 2
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days for the initial subjects in order to minimise the risk of 
toxicity.
Laboratory methods
These have been described in Chapter 2.
Statistical Analysis
Repeated measures analysis of variance or covariance was undertaken 
to compare with placebo the effects of the different doses on blood 
pressure, heart rate, plasma angiotensin converting enzyme and renin 
activity, aldosterone, adrenaline and noradrenaline levels. The 
pretreatment blood pressure and pretreatment aldosterone levels were 
taken as covariates in order to limit the variation caused by 
examining parallel groups. Where appropriate, confidence intervals 
were constructed using Dunnet’s ’t* statistic (54) for the 
difference between treated groups and placebo, making allowance for 
the multiple comparisons. The plasma hormone data were transformed 
to logarithms before analysis to normalise the distribution.
3.3 RESULTS
Tolerance
The drug was well tolerated by all subjects. Headache was frequently 
observed during both active treatment and placebo. Lightheadedness 
was noted with some intermediate doses but was not related to any 
postural fall in blood pressure. These symptoms were nearly all 
confined to the first and seventh days of treatment: the days of
intensive recordings. One subject complained of impotence during
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treatment with 4 mg daily. This resolved on completion of the study. 
There was no change in the screening tests either during or after 
treatment in any subject.
Angiotensin Converting Enzyme Activity
Perindopril inhibited plasma angiotensin converting enzyme in a dose 
related manner (p < 0.001, Figure 4). Sixteen mg daily produced 
about 90% inhibition 4 hours after dosing, with a fairly steady level 
of more than 80% inhibition beyond 1 to 12 hours after dosing on 
chronic once daily treatment. Even 24 hours after dosing, 
approximately 60% inhibition persisted with 8 mg and 16 mg daily. An 
increase in inhibition on the seventh day compared with the first was 
only noted with 1 mg, 2 mg and 4 mg daily (p < 0.001). Table 3 
displays the angiotensin converting enzyme inhibition as mean + SD 
for each time and dose.
Plasma Renin Activity
Four mg or more of perindopril raised plasma renin activity after the 
first dose (p < 0.001). A rise was also noted with 1 mg and 2 mg but 
the baseline renin was different in these two groups. All doses, 1 
to 16 mg, caused a further rise in renin after 7 days of treatment 
(Figure 4). The area under the curve for plasma renin activity 
(after logarithmic transformation) clearly shows a dose-related 
response (Figure 5). After 7 days of treatment, 4 mg and over 
maintained the renin above the normal range ( 4 - 1 2  ngAI.ml ^.hr ”* ) 
even 24 hours after dosing. The median renin activity and 95% 
confidence limits for each time and dose are shown in Table 4.
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Figure 4. Plasma angiotensin converting enzyme inhibition, renin 
activity and aldosterone concentrations following the first and 
seventh daily administrations of placebo (A ) and of 1 mg (X ),
2 mg (<>}, 4 mg (□), 8 mg (T) and 16 rag (■) of perindopril orally. 
The effects were significant by analysis of variance: ACE inhibition
(p < 0.001); renin activity (p < 0.001); and. aldosterone (p < 0.05), 
Each point represents the mean for six subjects.
Placebo 1 mg 2 mg
rime Mean SD Mean SD Mean SD
0 0.0 0.0 0.0 0.0 0.0 0.0
1 -1.5 5.5 10.2 18.6 13.9 21.0
2 18.5 24.1 16.2 21.1 34.3 18.3
4 0.6 11.2 31.2 26.2 41.3 23.9
6 3.4 10.4 22.2 26.6 36.7 25.5
8 -5.0 14.4 8.0 28.5 46.2 22.1
10 0.3 12.5 16.3 16.8 42.7 19.3
12 0.7 17.4 15.0 19.4 38.0 25.2
24 -4.6 9.6 1.0 25.7 28.6 29.3
144 6.6 9.4 13.1 29.6 49.8 20.1
145 6.4 17.7 29.5 24.0 54.5 18.8
146 11.9 32.8 35.5 11.9 53.8 21.0
148 17.4 32.1 37.1 12.0 61.8 27.0
150 8.6 22.8 44.1 9.3 62.5 23.6
152 0.5 9.5 37.4 19.6 65.7 18.6
154 -1.1 11.4 33.1 19.9 51.2 27.5
156 -3.1 15.7 37.1 13.4 55.0 23.4
168 -12.1 8.9 12.9 32.1 37.5 27.2
Table 3a. Plasma angiotensin converting enzyme inhibition following 
oral perindopril, expressed as 100 - (ACE/pretreatment ACE), n = 6.
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4 mg 8 mg 16 mg
rime Mean SD Mean SD Mean SD
0 0.0 0.0 0.0 0.0 0.0 0.0
1 24.4 16.1 40.8 41.9 64.2 14.6
2 45.7 15.6 67.5 27.0 85.6 7.6
4 54.9 21.3 74.6 11.9 91.1 4.1
6 63.0 32.7 77.0 12.0 90.5 3.5
8 61.5 8.1 74.0 13.1 87.2 3.2
10 62.2 11.0 76.1 17.2 79.1 5.7
12 66.5 5.1 69.3 17.9 86.8 6.3
24 37.1 4.2 63.5 14.7 69.0 6.5
144 28.6 16.8 48.0 14.7 60.2 10.5
145 53.7 20.4 72.5 9.3 84.2 7.6
146 68.5 14.3 76.4 8.5 89.6 3.8
148 78.1 14.4 76.4 12.2 89.4 5.6
150 70.4 13.6 76.0 12.5 87.3 3.4
152 58.3 10.5 72.2 12.8 84.5 4.5
154 59.9 13.0 67.0 8.0 82.1 4.6
156 57.0 14.8 66.4 9.6 84.1 2.7
168 19.2 20.6 55.3 16.4 57.3 14.7
3b. Plasma angiotensin converting enzyme inhibition, contini
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Figure 5. Areas under the curve for logarithm of plasma renin 
activity on the seventh day of treatment (mean + SD, n = 6). Units 
are given by hours x In (ngAI.ml” .hr” ).
Plasma renin activity Plasma aldosterone
Placebo
1 mg
ngAI.ml .hr -1 pg.ml”1
Time Median 95% limits Median 95% limits
0 2.5 1.9 - 3.1 130 116 - 146
4 6.6 5.1 - 8.4 93 82 - 105
8 4.5 3.5 - 5.7 102 91 - 115
24 2.1 1.6 - 2.6 132 117 - 148
144 1.5 1.2 - 1.9 133 118 - 149
148 4.8 3.8 - 6.1 96 86 - 108
152 2.7 2.1 - 3.4 89 79 - 100
168 2.7 2.1 - 3.4 127 113 - 142
0 1.5 1.2 - 1.9 72 64 - 81
4 4.2 3.3 - 5.3 54 48 - 60
8 2.8 2.2 - 3.6 57 50 - 64
24 2.0 1.5 - 2.5 66 58 - 74
144 3.8 3.0 - 4.8 75 66 - 84
148 11.3 8.9 - 14.4 52 46 - 58
152 6.5 5.1 - 8.3 50 44 - 56
168 4.2 3.2 5.5 79 70 _ 91
Table 4a. Plasma renin activity and aldosterone levels following 
oral perindopril. As the data were analysed after logarithmic 
transformation, the median and 95% confidence limits for each time 
are shown, n = 6. Renin was raised by active treatment (p < 0.001! 
and aldosterone was depressed (p < 0.05). Normal ranges for renin 
and aldosterone are 4 - 1 2  ngAI.ml .hr and 12 - 125 pg.ml 
respectively.
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Time
Plasma renin activity
-1 -1 
ngAI.ml .hr
Median 95% limits
Plasma aldosterone 
-1
pg.ml 
Median 95% limits
2 mg
4 mg
0 2.1 1.6 - 2.6
4 5.1 4.0 - 6.5
8 3.5 2.8 - 4.5
24 2.2 1.7 - 2.8
144 4.7 3.7 - 6.0
148 16.2 12.8 - 20.5
152 9.0 7.1 - 11.5
168 6.5 5.1 - 8.3
0 3.3 2.6 - 4.3
4 10.3 8.1 - 13.1
8 3.5 2.8 - 4.5
24 6.1 4.6 8.1
144 10.1 7.9 - 12.8
148 28.0 22.0 - 35.6
152 31.4 24.7 - 39.9
168 8.2 6.1 - 11.0
70 62 - 78
49 44 - 55
62 55 - 70
68 60 - 76
89 79 - 100
65 58 - 73
52 47 - 59
89 79 - 100
65 58 - 73
48 43 - 55
40 35 - 45
73 64 - 82
77 68 - 86
54 48 - 60
66 58 - 75
67 58 _ 77
Table 4b. Plasma renin activity and aldosterone levels, continued.
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8 mg
16 mg
Plasma renin activity Plasma aldosterone
-1 -1 -1  
ngAI.ml .hr pg.ml
Time Median 95% limits Median 95% limits
0 5.0 3.9 - 6.3 125 111 - 140
4 17.2 13.5 - 21.8 86 76 96
8 11.1 8.7 - 14.0 79 70 - 89
24 6.3 5.0 - 8.1 114 101 - 128
144 15.6 12.3 - 19.7 96 85 - 108
148 38.7 30.5 - 49.0 72 64 - 81
152 23.1 18.2 - 29.2 79 71 89
168 18.1 14.3 - 23.0 101 90 - 114
0 4.1 3.2 - 5.2 92 82 - 103
4 12.9 10.2 - 16.3 67 60 - 76
8 10.5 8.3 - 13.3 62 55 - 70
24 4.8 3.8 - 6.1 92 81 - 103
144 25.0 19.7 - 31.7 119 106 - 133
148 67.9 53.5 - 86.1 84 75 - 94
152 32.1 25.3 - 40.7 92 82 - 103
168 31.4 24.8 - 39.9 115 103 - 129
Table 4c. Plasma renin activity and aldosterone levels, continued.
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Plasma Aldosterone
The pretreatment aldosterone levels in several treatment groups 
differed from those in the placebo group. Correction for this 
difference was made initially by expressing the results as a 
percentage of the pretreatment level before analysis. The variation 
in the results obtained concealed any significant difference which 
may have been present (120). Subsequent examination of the raw data 
by analysis of covariance revealed a treatment effect (p = 0.034) and 
treatment-time interaction (p = 0.01). The data are displayed in 
Figure 4 and are shown more fully in Table 4.
Plasma Adrenaline
Perindopril had no effect on the plasma adrenaline levels at the 
times of sampling (p = 0.59, Table 5).
Plasma Noradrenaline
The plasma noradrenaline levels were not altered by active treatment 
(p = 0.99). Plasma catecholamine values are shown in Table 5.
Blood Pressure
No significant change in systolic blood pressure or supine diastolic 
blood pressure was detected. Erect diastolic blood pressure fell 
with active treatment (p = 0.023), particularly with 16 mg of 
perindopril. Supine heart rate was not altered by active treatment 
(p = 0.13), but a treatment-time interaction was present for erect 
heart rate (p = 0.017). Comparison of the heart rates at individual 
times after dosing reveals that perindopril 16 mg daily caused a 
significant rise in heart rate only in one recording after one week’s 
treatment. The erect blood pressure and heart rate data are
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Plasma noradrenaline 
-1
nmol.1
Plasma adrenaline 
-1
nmol.1
Dose
1 mg
Time Median 95% limits Median 95% limits
0 0.7 0.4 - 1.2 0.4 0.1 - 1.1
4 0.7 0.3 - 1.9 0.4 0.1 - 0.9
8 0.7 0.3 - 1.3 0.2 0.1 - 0.4
24 0.9 0.4 - 2.1 0.3 0.1 - 0.8
144 0.7 0.3 - 1.6 0.4 0.1 - 2.0
148 0.9 0.5 - 1.7 0.3 0.2 - 0.6
152 0.7 0.3 - 1.7 0.2 0.1 - 0.3
168 0.9 0.4 - 2.0 0.3 0.1 - 0.6
0 1.6 1.1 - 2.2 0.3 0.1 - 0.6
4 1.7 1.2 - 2.5 0.2 0.1 - 0.2
8 1.6 1.1 - 2.3 0.2 0.1 - 0.4
24 1.8 1.5 - 2.2 0.1 0.0 - 0.4
144 2.0 1.3 - 3.2 0.2 0.1 - 0.7
148 1.9 1.2 - 3.0 0.2 0.1 - 0.4
152 1.5 1.0 - 2.1 0.1 0.1 - 0.3
168 1.6 1.3 - 2.0 0.3 0.2 - 0.4
Plasma catecholamines after oral perindopril , n = 6.
The data were analysed after logarithmic transformation. There was 
no significant change from placebo (noradrenaline, p = 0.59; 
adrenaline, p = 0.99). Normal ranges are 0.3 - 7.5 nmol.l  ^ and 
0.0 - 1.0 nmol.l"** for noradrenaline and adrenaline respectively.
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Plasma noradrenaline 
nmol.1"^
Plasma adrenaline 
nmol.l *
Dose Time Median 95% limits Median 95% limits
2 mg 0
4
8
24
144
148
152
168
2.0 1.0 - 4.3 0.3 0.2 - 0.4
2.0 1.5 - 2.7 0.2 0.1 - 0.4
1.3 1.0 - 1.7 0.1 0.1 — 0.3
1.7 1.3 — 2.2 0.2 0.1 — 0.3
2.7 1.9 - 3.8 0.2 0.1 - 0.2
2.0 1.4 - 2.9 0.2 0.1 - 0.3
1.5 0.9 - 2.6 0.1 0.1 - 0.4
2.2 1.4 - 3.5 0.2 0.1 - 0.4
4 mg 0 1.6 1.2 - 2.2 0.3 0.2 - 0.5
4 1.7 1.3 - 2.2 0.1 0.0 - 0.4
8 1.5 1.1 - 2.2 0.2 0.1 - 0.3
24 2.1 1.4 - 3.1 0.3 0.2 - 0.4
144 1.9 1.6 - 2.4 0.2 0.1 - 0.4
148 2.0 1.8 - 2.2 0.1 0.0 - 0.4
152 2.2 1.4 - 3.2 0.2 0.1 - 0.4
168 2.8 2.0 - 4.0 0.3 0.2 — 0.4
Table 5b. Plasma catecholamines (continued).
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Plasma noradrenaline Plasma adrenaline
nmol.l'-1 nmol.l-1
Dose Time Median 95% limits Median 95% limits
8 mg 0 1.1 0.6 - 2.4 0.6 0.2 - 1.8
4 1.4 0.7 - 2.9 0.4 0.3 - 0.7
8 1.2 0.6 - 2.4 0.3 0.2 - 0.5
24 1.1 0.4 - 2.8 0.4 0.2 - 0.8
144 1.1 0.5 - 2.2 0.5 0.2 - 1.1
148 1.1 0.4 - 2.7 0.3 0.2 - 0.4
152 1.0 0.5 - 2.1 0.2 0.1 - 0.5
168 1.5 0.4 - 5.2 0.3 0.2 - 0.7
16 mg 0 1.8 1.4 - 2.4 0.9 0.5 - 1.5
4 2.3 1.8 - 3.0 0.6 0.3 - 1.1
8 1.3 0.7 - 2.4 0.4 0.2 - 0.9
24 2.4 1.7 - 3.4 0.7 0.3 - 1.5
144 2.1 1.5 - 2.9 0.5 0.2 - 1.1
148 2.3 1.9 - 2.7 0.6 0.2 - 1.7
152 1.9 1.4 - 2.6 0.4 0.2 - 1.4
168 2.5 1.8 _ 3.5 0.7 0.4 1.2
Table 5c. Plasma catecholamines (continued).
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displayed in Figure 6 and the 95% confidence intervals for a 
difference between perindopril-treated and placebo groups are given 
in Tables 6 to 8.
3.4 DISCUSSION
Perindopril was well tolerated in doses of up to 16 mg daily for 
seven days. The incidence of minor symptoms was similar in all 
groups, including placebo. Although impotence occurred in one 
subject taking 4 mg, this cannot with certainty be attributed to the 
drug. No untoward effect was found on routine physical examination 
or laboratory screening. The effects of perindopril on plasma 
angiotensin converting enzyme were dose-dependent in the range 
studied. With 16 mg, peak inhibition of 90% was achieved and 
significant inhibition persisted, around 60%, 24 hours after dosing 
with 8 mg or 16 mg. As would be expected, plasma renin activity was 
elevated by active treatment. Doses of 4 mg and over caused the 
plasma renin activity to be maintained above the normal range.
Despite the profound elevation of plasma renin activity, the 
reduction in plasma aldosterone levels was small and variable. The 
normal range for aldosterone is wide, however, and the parallel group 
design of the study made detection of changes in aldosterone 
relatively difficult.
Perindopril clearly lowered erect diastolic blood pressure. It may 
be difficult to demonstrate hypotensive activity in normal subjects, 
particularly when no salt restriction is imposed. Thus, the lack of
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change in supine pressure is not unexpected. Some increase in heart 
rate occurred after 7 days’ treatment at the highest dose. This is 
in contrast to the reported effects of other angiotensin converting 
enzyme inhibitors (88,143,151) and perindopril acutely (Chapter 5).
It may be that the large dose of perindopril caused volume depletion 
after several days’ treatment and that this produced a reflex 
tachycardia.
The absence of any effect of perindopril on circulating catecholamine 
levels is consistent with results after enalapril (143).
The profile of angiotensin converting enzyme inhibition after 
perindopril is different to that seen after captopril (170) and 
enalapril (143): perindopril causes longer lasting inhibition for a
given peak effect. Nevertheless, since enalapril is recognised to 
possess antihypertensive activity lasting for 24 hours or more after 
a 10 rag oral dose, when about 40% angiotensin converting enzyme 
inhibition persists (143), it appears reasonable to infer from our 
data with perindopril that a useful clinical dose will fall in the 
range 4 - 16 mg.
In conclusion, perindopril appears to be a safe and well tolerated 
inhibitor of plasma angiotensin converting enzyme in man. The 
effects on the renin angiotensin system and blood pressure are 
predictable. Further studies in volunteers and hypertensive patients 
are justified. An appropriate dose for these studies would appear to 
be of the order of 8 to 10 mg.
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CHAPTER 4
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EFFECTS OF INTRAVENOUS S-9780
4.1 INTRODUCTION
Perindopril is hydrolysed after absorption to its active diacid 
metabolite, S-9780. Some knowledge of the dynamic effects and 
pharmacokinetics of S-9780 is necessary for full interpretation and 
extrapolation of the studies of the effects of oral perindopril.
This study was designed to gather this necessary data. Since S-9780 
is poorly absorbed, intravenous administration was chosen. This 
study was the first occasion on which S-9780 was given intravenously 
to man.
4.2 METHODS 
Subjects
Eight normotensive male volunteers were recruited after screening by 
history, physical examination, urinalysis, electrocardiogram and 
routine laboratory tests of haematology and serum biochemistry to 
ensure good health. Written informed consent was obtained from all 
subjects and the study design was approved by the local ethical 
committee. The mean age of the volunteers was 26 years (range 18 - 
43), their mean weight was 72 kg (range 65 - 78) and their mean 
height was 181 cm (range 173 - 190) (Table 9). No salt restriction 
was imposed.
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Subject Age Height Weight
years cm kg
1 18 190 78
2 23 185 73
3 23 190 76
4 21 184 77
5 23 178 70
6 30 173 67
7 29 176 72
8 43 173 65
Mean 26 181 72
SD 8 7 5
Table 9. Demographic data for the volunteers studied.
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study Design
This was a double blind comparison of three intravenous doses of 
S-9780 with placebo. The subjects were randomly allocated to the 
rows of a balanced latin square to determine order of treatment.
Thus, each volunteer attended on four occasions at least a week 
apart, and was given placebo, 1 mg, 2 mg or 4 mg of S-9780 on each 
occasion.
The subjects arrived at the Clinical Pharmacology Research Unit at 
0830 hours on each study day. They had fasted since 2200 hours on 
the previous night and had avoided all drugs for the previous two 
weeks. No smoking, caffeine or alcohol ingestion was permitted 
during the study. An indwelling venous cannula was inserted in to an 
antecubital vein and the subjects rested until the start of the 
study.
Blood pressure and heart rate were measured, in duplicate after 10 
minutes' supine rest and 5 minutes standing, before and at the 
following intervals after dosing: 20, 40, 60, 80, 100 minutes, 2, 3,
4, 6, 8, 24 and 48 hours. Blood samples were drawn for plasma 
angiotensin converting enzyme activity before dosing and at the 
following intervals after dosing: 5, 10, 15, 20, 30, 40, 50, 60, 80,
100 minutes, 2, 3, 4, 6, 8, 24 and 48 hours. Samples were also 
collected for plasma renin activity, aldosterone, adrenaline and 
noradrenaline levels pre-dosing and after 4, 8 and 24 hours. Further 
samples were collected for assay of S-9780 in plasma and 
investigation of pharmacokinetic profiles. These results are 
presented in Chapter 7.
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At 0900 hours, 2 ml of normal saline containing the appropriate 
amount of S-9780 was injected as an intravenous bolus to the 
contralateral arm to the cannula. The subjects remained fasting for 
a further 2 hours but were then given a light standard breakfast (two 
slices of toast and a glass of milk) followed after the 4 hour 
recording by a light lunch. Free fluids were permitted from this 
time. The volunteers remained seated or supine for the first 8 hours 
of each study period but were then allowed home.
The volunteers were questioned about any symptoms they experienced at 
each blood pressure recording time and the pre-study screening tests 
were repeated after completion of the study.
Laboratory Methods
These have been fully described in Chapter 2.
Statistical Analysis
An effect of treatment order on any of the parameters which were 
measured was excluded by repeated measures analysis of variance 
before subsequent analysis. Repeated measures analysis of variance 
was employed to compare with placebo the effects of the different 
doses of S-9780 on all of the parameters measured. The plasma hormone 
data were transformed to logarithmic values before analysis in order 
to normalise the distribution.
Where a significant treatment effect or time-treatment interaction 
was present (p < 0.05), the effects of the various doses were then 
compared with placebo at the individual times after dosing by using
104
Dunnett's method for comparison of multiple treatment means with a 
single control (54).
4.3 RESULTS 
Tolerance and Safety
The drug was generally well tolerated. Three subjects were 
completely asymptomatic. One complained of headache after both 1 mg 
and 4 mg of S-9780, one subject had headache only after 1 mg and 
another subject had headache only after 4 mg of S-9780. The 
remaining two subjects felt tired after treatment with 1 mg and 2 mg 
of S-9780 respectively. There was no evidence of any toxicity on 
routine urinalysis or laboratory tests of haematology and 
biochemistry.
Plasma Angiotensin Converting Enzyme Activity
Each dose of S-9780 examined caused immediate and maximal inhibition 
of plasma angiotensin converting enzyme. There was no significant 
difference between the profiles of inhibition by 1, 2 or 4 mg 
(Figure 7).
Plasma Renin Activity
Intravenous S-9780 caused elevation of plasma renin activity
(p < 0.0001), when measured at 4 and 8 hours after dosing (Table 10).
After 24 hours, plasma renin activity had almost returned to normal.
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Figure 7. Inhibition of plasma angiotensin converting enzyme 
following acute intravenous administration of S-9780 1 mg (X ), 
2 mg (0 ) and 4 mg ([]) and of placebo (A ) . There was no 
significant difference between the effects of the active doses.
Plasma renin activity Plasma aldosterone
- 1 -1  
ngAl.ml pg.ml
hours median 95% limits median 95% limits
0 2.2 1.4 - 3.5 103 60 - 177
4 4.5 2.4 - 8.2 65 46 - 93
8 2.5 2.1 - 3.1 60 37 - 97
24 2.0 1.6 - 2.6
1 mg 0 2.6 1.8 - 3.7 86 56 - 130
4 14.1 4.8 - 41.3 59 28 - 128
8 8.6 4.5 - 16.4 67 45 - 102
24 3.9 2.7 - 5.7
2 mg
4 mg
0 1.9 1.4 - 2.7 89 71 - 112
4 18.6 7.5 - 46.0 48 32 - 73
8 8.0 4.6 - 14.2 57 37 - 87
24 4.0 2.7 - 5.8
0 2.1 1.4 - 3.2 78 51 - 121
4 35.1 30.3 - 40.8 56 40 - 80
8 11.1 6.6 - 18.6 58 40 - 85
24 5.0 3.0 — 8.5
Table 10. Plasma renin activity and aldosterone levels after 
intravenous doses of S-9780. The data were analysed after 
logarithmic transformation, therefore the median and 95% 
confidence limits are used; n = 8 throughout. Analysis of 
variance confirmed significant changes after treatment for 
renin (p < 0.0001) but not for aldosterone (p = 0.46).
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Plasma Aldosterone
No effect of treatment on plasma aldosterone levels was detected at 
the times of sampling (Table 10).
Plasma Catecholamines
No significant change in either plasma noradrenaline or adrenaline 
was detected after intravenous S-9780. The data are shown in Table 
11.
Blood Pressure and Heart Rate
Erect diastolic blood pressure fell after intravenous S-9780 
(p < 0.01). Within 20 minutes of dosing, 4 mg had lowered the 
diastolic pressure by 9 mmHg compared with placebo (95% confidence 
limits -17.1 to -0.7 mmHg) and the pressure was still at similar
levels after 24 hours (95% confidence limits -16.8 to -0.5 mmHg). A
trend towards lower values was also seen for erect systolic and
supine blood pressures but these were not statistically significant.
No significant change in heart rate occurred (Figure 8).
4.4 DISCUSSION
The volunteers tolerated intravenously administered S-9780 very well. 
The complaints of minor symptoms such as headache and tiredness were 
restricted to the days of active treatment but there was a total of 
only six complaints out of twenty four days when active treatment was 
administered and there was therefore no conclusive evidence that they 
were drug induced. In particular, there was no instance of 
symptomatic hypotension.
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Noradrenaline Adrenaline
nmol..1"
-1
nmol. 1
hours median 95% limits median 95% limits
Placebo 0 1.2 0.6 - 2.2 0.4 0.2 - 0.7
4 2.1 1.3 - 3.4 0.4 0.3 - 0.6
8 1.3 0.5 - 3.4 0.3 0.2 - 0.5
1 mg 0 0.7 0.3 - 1.4 0.4 0.2 - 0.7
4 1.1 0.4 - 2.5 0.4 0.3 - 0.6
8 0.8 0.4 - 1.4 0.3 0.2 - 0.5
2 mg 0 1.0 0.7 - 1.6 0.3 0.2 - 0.4
4 1.4 1.0 - 2.0 0.2 0.2 - 0.4
8 1.1 0.7 - 1.6 0.2 0.1 - 0.4
4 mg 0 1.0 0.5 - 2.0 0.3 0.2 - 0.5
4 1.8 1.1 - 2.9 0.3 0,2 — 0.6
8 1.7 1.0 2.9 0.4 0.3 - 0.6
Table 11. Plasma catecholamine levels after intravenous doses of S-9780, 
The data were analysed after logarithmic transformation, therefore the 
median and 95% confidence limits are displayed; n = 7 throughout.
There was no significant change compared with placebo (noradrenaline, 
p = 0.07; adrenaline, p = 0,21).
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Figure 8. Mean standing blood pressure and heart rate after placebo 
correction following acute intravenous administration of 1 mg (%),
2 mg (0) and 4 mg (□) of S-9780, n = 8. Only the effects on 
diastolic pressure were significant by analysis of variance (p < 0.01
The effects on blood pressure were modest but convincing. No salt 
restriction had been imposed and the subjects were normotensive, 
therefore a marked hypotensive response would not be expected. The 
lack of reflex tachycardia despite a fall in blood pressure provides 
further evidence that this is a feature of angiotensin converting 
enzyme inhibitors in general (88,143,151).
In view of the clear dose-related response of angiotensin converting 
enzyme to oral perindopril in doses of 1 to 16 mg (Chapter 3), it is 
slightly surprising that there was no detectable difference in the 
extent of enzyme inhibition following the various doses of S-9780. 
This suggests that even 1 mg of intravenously administered S-9780 has 
an effect at least as great as 16 mg of perindopril orally. Thus, it 
offers evidence that the bioavailability of the active metabolite is 
relatively low in man.
The response of plasma renin activity was dose related, however, with 
effects still detectable 24 hours after dosing. Despite this, the 
aldosterone levels did not change significantly although the 
confidence limits demonstrate that the power of this study to detect 
such a change was low.
In conclusion, S-9780 caused predictable changes in the renin 
angiotensin system and moderate lowering of blood pressure in normal 
salt replete volunteers. The drug was well tolerated and appears 
safe for further clinical study.
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CHAPTER 5
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AUTONOMIC EFFECTS OF PERINDOPRIL
5.1 INTRODUCTION
The preceding studies with perindopril have confirmed that it is a 
potent inhibitor of plasma angiotensin converting enzyme, with a long 
duration of action.
The withdrawal of the vasoconstrictor action of angiotensin II 
following angiotensin converting enzyme inhibition would result in 
arteriolar vasodilatation. The consistent reports of an absence of 
reflex tachycardia or sympathetic activation after converting enzyme 
inhibitors (88,143,151) are, however, at variance with the 
haemodynamic and neuro-endocrine responses to classical peripheral 
arterial vasodilators such as hydralazine (126).
This unusual haemodynamic profile has given rise to the concept that 
angiotensin converting enzyme inhibition may lead to consequences 
more complex than a simple removal of the vasoconstrictor role of 
angiotensin II. Specifically, a further effect of angiotensin II 
removal on autonomic function or baroreflex integrity has been 
suggested (210). Additionally, several other interpretations have 
been advanced, including an effect on venous capacitance (194), 
increased compliance of large arteries (121) and parasympathetic 
activation (2,27,188).
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While enhanced cardiac vagal tone has been reported after captopril 
(27,188), enalapril (2) and lisinopril (2), it remains to be 
established whether this is a common property of angiotensin 
converting enzyme inhibitors or a specific feature of the individual 
drugs.
The aim of the present study was to examine the effects of 
perindopril on autonomic function and exercise performance, after 
single oral doses in healthy subjects.
5.2 METHODS
Subjects and Study Design
This was a double blind, randomised, placebo controlled, crossover 
study. Prior approval of the protocol was obtained from the local 
ethical review committee. Ten healthy, normotensive male subjects, • 
aged 18 - 28 years and weighing 54 - 93 kg, gave written informed 
consent to participate in the study. The subjects were judged healthy 
by history, clinical examination and by biological (SMA-12), 
heamatological and electrocardiographic screening prior to entry to 
the study. Their sodium status was established by 24 hour urine 
collection: the mean excretion was 226 + 95 mmol in 24 hours.
On two study days, two weeks apart, the volunteers attended the 
Clinical Pharmacology Research Unit at 0830 hours, 1 hour after a 
standard light breakfast having avoided coffee, tea, alcohol and 
cigarettes for 12 hours. They were allowed to rest for 30 minutes 
before the study commenced.
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Placebo or 8 mg of perindopril in identical capsules was administered 
orally with 200 ml of water. Blood pressure and heart rate were 
recorded in duplicate after 10 minutes’ supine rest and 1, 2 and 5 
minutes standing, before and 1, 2, 4, 6 and 8 hours after dosing. A 
light snack was allowed after the two hour recording. Blood pressure 
was measured by a semiautomatic sphygmomanometer (Sentron; Bard 
Biomedical) and heart rate recorded by praecordial electrocardiogram 
electrodes connected to a Grass Polygraph model 7B IB (Quincy; Mass., 
USA). Where required, heart periods were measured from the 
electrocardiograph tracing as the beat to beat intervals.
Autonomic Reflex Tests
The following tests of autonomic function were undertaken in the 
stated order between 4 and 5 hours after dosing, i.e. at the time of 
maximal drug effect. At least five minutes were allowed between each 
procedure or until haemodynamic variables returned to pre-manoeuvre 
levels, whichever was the longer.
1. Standing to lying test.
After 5 minutes of standing erect, subjects lay down on a bed. Heart 
rate was recorded over the last 10 beats before lying down and for 30 
seconds after. The standing to lying ratio was calculated as the 
ratio of the mean erect heart period to the shortest heart period in 
the first 10 beats after starting to lie down (15).
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2. Forearm isometric exercise.
Subjects were required to maintain 30% of pre-determined maximum hand 
grip on a modified sphygmomanometer for 2 minutes. Blood pressure 
and heart rate were measured before and at 1 minute intervals during 
exercise. The increase in blood pressure induced by the test is due 
to sympathetic stimulation.
3. Valsalva's manoeuvre.
The Valsalva's manoeuvre was performed in duplicate. In the supine 
position subjects maintained forced expiration to hold a column of 
mercury in a modified sphygmomanometer at 50 mmHg for 15 seconds. The 
electrocardiograph was continuously recorded. Blood pressure was 
measured before the manoeuvre and after termination of expiration, 
which coincides with the pressure overshoot (178). The difference 
between pre and post Valsalva blood pressures, and the ratio of the 
longest heart period during the manoeuvre to the shortest after, were 
used in the data analysis.
4. Diving reflex.
Volunteers sat for 5 minutes with faces held 3-4 cm above a basin of 
water at 18-20 C. On instruction, without taking a deep inspiration, 
they lowered their face into the water and remained immersed for as 
long as was tolerable, but for at most 30 seconds. The 
electrocardiograph was recorded throughout the procedure. The 
difference between the heart rate before the test and the minimum 
heart rate during the test was used in the analysis. The profound
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bradycardia induced by the test is due to parasympathetic stimulation 
(60).
5. Cold pressor test.
Sympathetic efferent integrity was assessed by the cold pressor test. 
Supine subjects immersed one hand to the wrist in melting ice for 2 
minutes. Heart rate and blood pressure were recorded in the 
contralateral arm before and at 1 minute intervals. The results are 
expressed as the maximum change observed over the 2 minutes.
6. Heart rate variation with deep breathing.
After lying supine on a bed for 10 minutes, volunteers undertook 
maximum inspiration and expiration for 6 cycles each lasting 10 
seconds, with continuous electrocardiograph recording. The variation 
in heart rate (an increase in inspiration and a decrease in 
expiration) is due to changes in vagal tone (217). The results are 
presented as the maximum difference between inspiratory and 
expiratory heart rate in the final cycle of respiration.
7. Dynamic exercise test.
Dynamic exercise performance was assessed by bicycle ergometry at 
175 W for 5 minutes. Blood pressure and heart rate were recorded 
before exercise and during the 5th minute of exercise. The increase 
in blood pressure and heart rate during exercise was used in data 
analysis.
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Statistical Analysis
All results are expressed as mean + SD. Data obtained from 
cardiovascular measurements were evaluated by repeated measures 
analysis of variance. The blood pressure and heart rate responses to 
autonomic tests were compared by paired Student's 't' test (two 
tailed). The null hypothesis was rejected at p < 0.05.
5.3 RESULTS 
Tolerance
Perindopril was well tolerated, and no untoward effect was reported 
spontaneously or on enquiry. No haematological or biochemical
abnormality was detected on post study evaluation.
Blood Pressure and Heart Rate
Compared with placebo, perindopril lowered the average blood pressure 
over the 8 hour study period: the difference in average pressure was
11/7 mmHg in the supine position (p=0.001/p=0.045) and was 13/5 mmHg 
after 1 minute standing (p=0.001/p=0.006). The pre-treatment blood 
pressure was 119 + 8/64 + 7 mmHg in the supine position and 121 + 19/ 
7 0 + 9  mmHg standing. The effect on blood pressure was apparent at 1 
hour and persisted for at least 8 hours. The fall in blood pressure
after perindopril was not associated with a change in heart rate in
the supine or standing position (Figures 9 & 10).
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The fall in pressure was significantly different from placebo by 
analysis of variance.
standing to Lying Test, Deep Breathing Test, Diving Reflex 
The effect of perindopril on the tests of parasympathetic 
responsiveness is shown in Table 12. Following placebo, the 
immediate heart rate response to lying down was a transient increase 
in heart rate, which was maximal at the 3rd or 4th beat, and 
thereafter there was a progressive fall in heart rate. Perindopril 
did not alter the standing to lying ratio although the 95% confidence 
interval for the paired difference, active - placebo, was -0.3 to 1.3,
On placebo, the maximum heart rate change during deep breathing was 
25.7 + 7.5 beats per minute. This was increased to 30.4 + 6.0 
beats.min on perindopril (p < 0.005). The 95% confidence
interval for the difference between perindopril and placebo was 1.6 
to 7.8. This result is shown in Figure 11.
Perindopril did not significantly change the bradycardia induced by 
apnoeic facial immersion in water (the diving reflex).
Isometric Exercise, Dynamic Exercise and Cold Pressor Test 
The response to tests of sympathetic function is shown in Table 13. 
The blood pressure before the procedure tended to be lower on active 
treatment. Perindopril had no significant effect on the pressor or 
the chronotropic changes induced by cold stress or by isometric or 
dynamic exercise. Perindopril did, however, significantly increase 
the pulse pressure during dynamic exercise: this rose by
10 + 20 mmHg from 5 0 + 1 1  mmHg on placebo, but rose by 36 + 19 mmHg 
from 4 9 + 1 0  mmHg after perindopril. The 95% confidence interval 
for the paired difference in pulse pressure increase was 5 to 
57 mmHg. Diastolic blood pressure did not rise during dynamic
117
Placebo Perindopril
1. Deep breathing test 
Minimum heart rate
(beats.min" ) 52.3 + 10.2 51.5 + 8.8
A heart rate
(beats.min"^) 25.7 + 7.5 30.4 + 6.0**
2. Diving reflex
Pre test heart rate
(beats.min ^) 70.3 + 10.5 73.0 + 8.9
A heart rate
(beats.min ^) -26.3 +11.8 -26.4 +8.5
Table 12. The effect of perindopril on the heart rate variation with 
deep breathing and the diving reflex (n = 10, mean + SD, ** p < 0.005).
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Figure 11. The effect of perindopril on the heart rate-variation 
with deep breathing; ** p < 0.005 (n = 10, mean + SD).
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exercise after perindopril. Similarly, the pulse pressure increased 
during isometric exercise on active treatment (+5.1 + 14.5 mmHg) 
while it fell as expected on placebo (-7 + 9.5 mmHg). The 95% 
confidence interval for the paired difference was 0.5 to 25.1 mmHg.
Valsalva's Manoeuvre
The results of the response to the Valsalva manoeuvre are shown in 
Table 14. There was no difference in the pressure overshoot or the 
Valsalva ratio between placebo and perindopril.
5.4 DISCUSSION
These results show that perindopril caused a modest but significant 
reduction in the blood pressure of salt replete, normotensive 
volunteers, in keeping with earlier reports of its long-lasting 
inhibition of the renin angiotensin system (116, Chapters 3 & 4).
The fall in blood pressure was not associated with reflex increases 
in heart rate, consistent with previous experience with other 
angiotensin converting enzyme inhibitors (88,143). This observation 
further confirms that the absence of reflex cardioacceleration is a 
general property of converting enzyme inhibition.
In the present study with perindopril, a wider array of autonomic 
function tests has been employed. Perindopril had no effect on 
cardiovascular changes during the cold pressor test, a reflection of 
efferent sympathetic integrity (92), and impaired neither isometric 
nor dynamic exercise performance. The only detectable consequence of
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perindopril was an increase in pulse pressure during exercise, 
consistent with an arteriolar dilator action following angiotensin II 
withdrawal. These observations accord with earlier reports with 
captopril (27,188), acute and chronic enalapril and lisinopril 
(2,143). Taken together, they suggest that the angiotensin II 
mediated facilitation of noradrenergic transmission which has been 
observed in vitro (186,225) may be of little clinical consequence in 
normal man. Parenthetically, the demonstration of preserved 
sympathetic responsiveness after angiotensin converting enzyme 
inhibition does not materially exclude small localised changes in 
cardiac sympathetic function, nor does it exclude modification of 
sympathetic function after lesser degrees of stimulation than 
isometric or dynamic exercise. Indeed, the observation of unchanged 
plasma noradrenaline levels after angiotensin converting enzyme 
inhibitors (2,143,188) despite blood pressure reduction, is itself 
indicative of a "relative blunting" of noradrenergic responses.
The preservation of the responses to the Valsalva manoeuvre and the 
lack of postural hypotension suggest that baroreceptor reflex 
function is unimpaired by perindopril.
The enhanced respiratory variation of heart rate with deep breathing, 
which is under vagal control (217), indicates increased 
parasympathetic responsiveness after perindopril. Although no 
statistically significant effect was detected on the immediate heart 
rate response to lying down, a test of vagal withdrawal (15), the 
confidence interval for the standing to lying ratio is consistent 
with enhanced vagal responsiveness. No effect was detected on the 
diving reflex, a test of maximal parasympathetic stimulation (60),
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suggesting that maximal vagal activity is unaltered.
However, the modification of vagal responses which has been reported 
after captopril (27,188), enalapril and lisinopril (2) and now with 
perindopril, implies that this autonomic effect is a general property 
of angiotensin converting enzyme inhibitors probably secondary to 
angiotensin II removal (3). This vagomimetic action of angiotensin 
converting enzyme inhibitors, together with an absence of the normal 
compensatory sympathetic response to hypotension, suggests that the 
balance between sympathetic and vagal activity is altered during 
converting enzyme inhibition. Whether vagal enhancement occurs to a 
similar degree in older or hypertensive subjects is not clear.
Angiotensin II exerts protean effects on autonomic mechanisms 
including central (119,129,177) and peripheral (166) vagal 
inhibition, as well as presynaptic facilitation of sympathetic 
transmission (186,225). In tissues such as the heart, dually 
innervated by both vagal and sympathetic neurones, the neuro­
transmitters interact not only by opposing effects on the effector 
cells, but also by a mutual prejunctional antagonism (128) which may 
be influenced by angiotensin II withdrawal. Whether the vagotonic 
effects of angiotensin converting enzyme inhibitors occur at central 
sites (119,129,177) or peripherally at the heart (166) is not clear. 
However, the central site of circulating angiotensin II's 
cardiovascular actions is in the area postrema (110), a zone outside 
the blood brain barrier (223), and is thus susceptible to changes in 
circulating angiotensin II. This makes it possible that both central 
and peripheral sites may be involved.
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In conclusion, absence of reflex tachycardia occurs with the 
angiotensin converting enzyme inhibitor, perindopril. Evidence is 
provided that enhanced cardiac vagal tone contributes to the 
cardiovascular effects of perindopril, and that this may be a feature 
of angiotensin converting enzyme inhibitors in general.
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CHAPTER 6
125
PERINDOPRIL IN HYPERTENSIVE PATIENTS
6.1 INTRODUCTION
Phase I studies with perindopril demonstrated potent and prolonged 
inhibition of angiotensin converting enzyme and hypotensive activity 
in salt replete normotensive volunteers {Chapters 3 to 5). The drug 
was well tolerated in doses of up to 16 mg once daily for periods of 
up to one week. Hypertensive patients would be expected to show 
greater sensitivity to the drug, however, and therefore a pilot study 
was designed to examine the tolerability of perindopril and its 
biochemical and haemodynamic effects in a small group of patients.
6.2 METHODS 
Patients
The inclusion and exclusion criteria for entry to the study are shown 
in Table 15. The patients underwent full history, physical 
examination and pre-study tests which included routine urinalysis, 
haematology, serum biochemistry and an electrocardiogram. Seven 
patients entered the study and all completed the protocol.
Recruitment stopped when a further large scale long term study of the 
drug was commenced locally. The mean age of the patients was 52 
years (range 23 - 65), their mean weight was 76.6 kg Irange 59.5 - 
105) and height was 167 cm (152 - 176); 2 of the T were female.
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INCLUSION CRITERIA
Age
Sex
Weight
B.P.
H.R.
1 8 - 6 5  years.
Males or post-menopausal females.
Within 15% of ideal.
145/95 - 200/115 (phase V supine) on two occasions several 
days apart, after a minimum of two weeks on no 
antihypertensive drugs.
50 - 90 min ^.
Consent Written informed consent to be granted.
EXCLUSION CRITERIA
Clinically significant disease other than hypertension. 
Clinically significant abnormality of pre-study laboratory data, 
other than electrocardiographic evidence of left ventricular 
hypertrophy solely.
Known or suspected secondary hypertension.
Asthma, eczema or serious allergic disease.
Medication in the two weeks before the study.
History of drug or alcohol abuse.
Previous exposure to captopril or enalapril.
Table 15. Entry criteria for patients.
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Blood pressure at entry was 180 + 22 / 104 + 10 mmHg (mean + SD). 
Twenty four hour sodium excretion was 155 mmol (range 98 - 216).
Study Design
This was a single blind study. The patients were given a two week 
course of placebo capsules followed by four weeks of treatment with 
4 mg of perindopril daily. After 2 weeks of active treatment, the 
investigators had the option of increasing the once daily dose to 
8 mg if the blood pressure had not fallen from the pretreatment level 
by 5%.
On the 8th day of the study (during placebo treatment), the 15th day 
(the first day of active treatment) and the 43rd day {final day of 
active treatment) the patients attended the Clinical Pharmacology 
Research. Unit at 0830 hours, having fasted since 2200 hours on the 
previous night. No smoking, caffeine or alcohol ingestion was 
permitted during the study. An indwelling venous cannula was sited 
in an antecubital vein and the patients rested until the start of the 
study.
Blood pressure and heart rate were measured, in duplicate after 10 
minutes’ supine rest and 5 minutes standing, before and at the 
following intervals after dosing: 1, 2, 4, 6, 8, 10, 12 and 24
hours. In addition, blood samples were drawn for plasma drug 
concentration and angiotensin converting enzyme activity at each of 
these times and samples were collected for plasma renin activity, 
aldosterone, adrenaline and noradrenaline levels pre-dosing and after 
4, 8 and 24 hours.
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At 0900 hours, capsules containing the appropriate treatment were 
administered orally with 200 ml of water. The subjects remained 
fasting for a further 4 hours and were then given a light standard 
lunch. Free fluids were permitted from this time. The patients 
remained seated or supine for the first 4 hours of each study period. 
The subjects were questioned about any symptoms they experienced at 
each blood pressure recording time and the pre-study screening tests 
were repeated after completion of the study.
Laboratory Methods
These have been fully described in Chapter 2.
Statistical Analysis
Repeated measures analysis of covariance was employed to compare with 
placebo the effect of perindopril on blood pressure and heart rate 
and on plasma aldosterone, adrenaline and noradrenaline levels. The 
pretreatment values from the placebo day were used as covariates for 
the data collected on that day. The pretreatment values from the 
first day of active treatment, i.e. Day 15, were used for all of the 
ensuing measurements. Plasma renin activity and angiotensin 
converting enzyme inhibition were examined by repeated measures 
analysis of variance. The plasma hormone data were transformed to 
logarithmic values before analysis in order to normalise the 
distribution.
Where a significant treatment effect or time-treatment interaction 
was present (p < 0.05), the effects on the three days were then 
compared with each other at the individual times after dosing by 
using the ’honestly significant difference’ method described by
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Tukey (220).
6.3 RESULTS 
Tolerance and Safety
All patients tolerated the drug well and none withdrew from the 
study. There was no evidence of any change in the routine laboratory 
tests during or after treatment. Four patients were asymptomatic 
throughout the study; one suffered mild postural dizziness and 
headache on both placebo and active treatment, one complained of mild 
chest tightness on one day during active treatment and the final 
patient experienced mild headache during both active and inactive 
treatment.
Blood Pressure and Heart Rate
Blood pressure settled slightly but not significantly over the second 
week of placebo treatment, from 173 + 1 7 / 9 7 + 7  mmHg supine and 
177 + 19 / 106 + 7 mmHg erect to 165 + 1 9 / 9 5 + 7  supine and 
168 + 1 6 / 1 1 0 + 1 1  mmHg erect (mean + SD). Even after taking these 
values as covariates for the subsequent pressures, there was a fall 
in pressure after the first dose of perindopril (p < 0.005) and this 
was maintained unchanged after four weeks of active treatment 
(Table 16). Heart rate did not significantly change. The blood 
pressure and heart rate profiles are shown in Figure 12.
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Pooled ANCOVA 
Placebo Acute Chronic SEM p
SUPINE
Systolic (mmHg) 163.9 145.2** 142.5** 3.4 0.005
Diastolic (mmHg) 92.7 83.5** 82.1** 1.7 0.002
Heart rate (min"^) 68.2 66.5 68.6 1.2 0.464
ERECT
Systolic (mmHg) 165.3 148.6** 151.3** 2.4 0.001
Diastolic (mmHg) 102.7 92.0** 92.5** 1.4 0.002
Heart rate (min ^) 75.7 77.1 81.0 1.6 0.096
Table 16. Blood pressure and heart rate in 7 patients, as mean of 
readings over 24 hours following dose. ** p < 0.01 compared with 
placebo. There was no significant difference between the acute and 
chronic days.
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Figure 12. Mean blood pressure and heart rate after placebo (A), 
perindopril acutely ( #  ) and after one month's treatment (O), n = 7. 
Blood pressure was significantly lower on both active days than on 
the placebo day even after correcting for baseline pressure by 
analysis of covariance (p < 0.005).
Angiotensin Converting Enzyme
Inhibition of plasma angiotensin converting enzyme was apparent 
within 1 hour of the first dose of perindopril and was maintained 
between 50% and 80% for most of the day. The inhibition 24 hours 
after the first dose was 49% + 20 whereas the 24 hour values on the 
43rd and 44th days were 39% + 27 and 28% + 45 respectively. There 
was no significant difference between the profiles for the acute and 
chronic days (Figure 13) when compared by repeated measures analysis 
of variance.
Plasma Renin Activity and Aldosterone
Perindopril caused an increase in plasma renin activity (p < 0.005) 
but had no detectable effect on plasma aldosterone levels (p = 0.21). 
The median values and 95% confidence intervals are displayed in 
Table 17.
Plasma Catecholamines
No change was detected in plasma adrenaline or noradrenaline levels 
during treatment with perindopril. The data are shown in Table 18.
6.4 DISCUSSION
The primary aim of this study was to establish whether the effects of 
perindopril which were seen in normal volunteers (Chapter 3) would be 
confirmed in hypertensive patients.
The excellent tolerability which had been reported in the normal 
subjects was also found in this small group of patients. Even with
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Figure 13. Mean percentage inhibition of plasma angiotensin 
converting enzyme after placebo {A ), perindopril acutely {#) and 
after one month's treatment (O), n = 7. The acute and chronic 
profiles did not differ significantly.
PLASMA RENIN 
ngAI.ml”
ACTIVITY
1.hr”1
PLASMA ALDOSTERONE
pg.ml””*
hours median 95% limits median 95% limits
Placebo 0 1.1 0.5 - 2.2 70 39 - 126
4 1.2 0.7 - 2.2 42 23 - 76
8 0.8 0.4 - 1.6 54 33 - 86
24 0.9 1.6 - 1.3 63 38 - 104
Acute 0 1.1 0.7 - 1.8 73 48 - 112
4 1.3 0.5 - 3.2 38 18 - 79
8 1.6 1.0 - 2.4 52 32 - 85
24 1.6 0.8 — 3*0 54 35 - 86
Chronic 0 2.1 0.8 - 5.7 67 50 - 90
4 2.4 0.8 - 7.9 36 24 - 53
8 2.7 0.8 - 8.6 40 26 - 61
24 2.6 1.3 - 5.4 59 37 - 95
Table 17. Plasma renin activity and aldosterone concentrations after
perindopril in hypertensive patients, n = 7. The data were 
transformed to logarithms prior to analysis. Plasma renin was 
altered by treatment (p < 0.005) but aldosterone did not change 
(p = 0.21). Normal ranges for renin and aldosterone are 
4 - 12 ngAI.ml .hr and 12 - 125 pg.ml respectively.
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PLASMA NORADRENALINE 
nM
PLASMA ADRENALINE 
nM
hours median 95% limits median 95% limits
Placebo 0 0.8 0.2 - 3.0 1.0 0.5 - 2.2
4 0.9 0.4 - 2.2 0.5 0.3 - 1.0
8 1.4 0.5 - 3.8 0.9 0.4 - 1.8
24 1.3 0.6 - 3.2 0.8 0.4 - 1.6
Acute 0 1.7 0.5 - 5.2 0.9 0.3 - 2.5
4 1.7 0.7 - 4.2 0.9 1.4 - 0.9
8 1.1 0.4 - 2.9 0.7 0.3 — 1.7
24 1.3 0.4 - 4.6 0.6 0.2 - 1.7
Chronic 0 1.0 0.4 - 2.6 0.8 0.5 — 1.3
4 1.1 0.5 - 2.6 0.6 0.3 — 1.3
8 0.7 0.2 - 2.0 0.7 0.3 - 1.4
24 0.8 0.3 - 2.0 0.8 0.3 — 1.9
Table 18. Plasma catecholamine levels after perindopril in
hypertensive patients, n = 7. The data were transformed to
logarithms before analysis. There was no effect on either 
noradrenaline (p = 0.22) or adrenaline (p = 0.97). Normal ranges 
are 0.3 - 7.5 nM and 0.0 - 1.0 nM for noradrenaline and adrenaline 
respectively.
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the longer exposure time of one month, no adverse effect was 
encountered which could be attributed to the drug.
The blood pressure lowering action of perindopril in normotensive 
volunteers was modest. This study in hypertensive patients was not 
designed to provide detailed assessment of the effect of the drug on 
blood pressure. Nevertheless, the blood pressure clearly fell after 
the first dose of perindopril compared to placebo, even when the 
slightly lower pretreatment pressure was taken into account. The 
effect on blood pressure persisted throughout the month of treatment. 
No symptomatic hypotension occurred. Thus the effect on blood 
pressure was predictable and useful, even in salt replete patients.
A significantly greater hypotensive effect would be anticipated if 
salt restriction or a diuretic were added (33,50,116,131). In accord 
with the studies in normal volunteers with perindopril at similar 
doses (Chapters 3, 4 & 5), with enalapril (143) and with captopril 
(27,188), no change in heart rate occurred. This is clearly a useful 
property for a vasodilator drug.
The degree of inhibition of plasma angiotensin converting enzyme 
which was achieved in the patients was comparable to that encountered 
in the normal volunteers. There was a trend towards reduced 
inhibition after four weeks’ treatment, however. This has been 
partially masked by the increase in dose of perindopril taken by some 
of the patients. Failure to detect inhibition of plasma angiotensin 
converting enzyme during chronic captopril treatment has been 
reported (155) but was almost certainly a spurious result due to the 
rapid decay of captopril in plasma in vitro (172).
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Despite this slight reduction in measured inhibition of angiotensin 
converting enzyme, plasma renin activity was still elevated after 
chronic treatment with perindopril. The median renin activity for 
the group was still at the lower end of the normal range for our 
laboratory, in contrast to the effect in normal volunteers 
(Chapter 3). The patients had considerably lower pretreatment renin 
activity, however, and their ages ranged up to 65 years. Both 
factors would tend to reduce the renin activity after treatment 
(4,213).
In common with the normal volunteers, the patients did not show any 
response of plasma aldosterone to treatment with perindopril. Once 
again this may be as a result of several factors: the variability in
the data and the small size of the study, the infrequent sampling for 
aldosterone or a minimal effect on the hormone levels. It remains 
clear, however, that significant reduction of plasma aldosterone 
levels is not necessary to achieve the hypotensive effect (211).
No stimulation of the sympathetic nervous system was detected in the 
patients, despite the relatively greater falls in blood pressure 
compared to the normal volunteers. Similar findings have been 
reported for captopril (211) and enalapril (143).
In conclusion, the results of this pilot study of the use of 
perindopril confirm that the biochemical and haemodynamic effects 
which were observed in normal volunteers are reproduced in 
hypertensive patients. Thus perindopril appears to be a safe, well 
tolerated and effective antihypertensive drug. The results justify 
proceeding to more extensive testing in patients.
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CHAPTER 7
137
PHARMACOKINETICS OF S-9780
7.1 INTRODUCTION
S-9780 is the active diacid metabolite of perindopril, which is 
liberated by the vivo ester hydrolysis of the latter drug 
after oral administration. No data on the pharmacokinetics of S-9780 
in man have been published. Studies in animals using radiolabelled 
S-9780 suggest that it follows triphasic disposition, with a long 
terminal phase (Institut de Recherches Internationales Servier; 
personal communication).
The present study examines the pharmacokinetics of S-9780 in healthy 
volunteers after oral administration of perindopril and after direct 
intravenous infusion of the active metabolite, S-9780. In 
particular, the aims were to establish whether the pharmacokinetics 
of S-9780 in man after intravenous administration were similar to the 
animal data, to estimate the terminal half-life of the drug and to 
test whether that half-life was relevant to the prediction of steady 
state concentrations. From the data after repeated oral dosing with 
perindopril, it was intended to test for linearity of the 
pharmacokinetics and to provide information which could be used to 
examine the concentration-effect relationship (Chapter 8).
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7.2 METHODS
Full descriptions of the protocols for the dose-ranging studies with 
oral perindopril and intravenous S-9780 in healthy volunteers were 
given in Chapters 3 and 4: only an outline is given here.
Oral perindopril was administered once daily for 7 consecutive days 
to parallel groups of 6 healthy volunteers, with each group receiving 
a different daily dose. On the days 1 and 7, blood samples were 
drawn pre-dosing and after 1, 2, 4, 6, 8, 10, 12 and 24 hours. On 
the intervening days, samples were taken before dosing. Although the 
study involved dosing with 1 to 16 mg of perindopril, S-9780 
concentrations were only assayed for the subjects taking 4, 8 or 
16 mg.
The study of the effects of intravenous S-9780 utilised a latin 
square crossover design such that 3 doses of S-9780 (1, 2 and 4 mg) 
or placebo were administered to each of 8 healthy volunteers and 
blood samples were collected at frequent intervals for 48 hours.
At each time when plasma was collected for estimation of angiotensin 
converting enzyme activity, an aliquot was retained for determination 
of S-9780 concentration, by the method described in Chapter 2.
Thus, two sets of kinetic data were obtained: nine plasma levels of
S-9780 after the first and the seventh doses of oral perindopril 
giving ’acute’ and ’chronic’ profiles at three doses, each in six 
subjects; and seventeen plasma levels following each dose of 
intravenous S-9780, giving a total of fifty-one samples, in each of 8
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s u b je c ts .
Kinetic analysis after oral perindopril
Nonlinear ordinary least squares regression analysis (134) was used 
to fit separately the acute and chronic data from each subject. Two 
models were tested; a one-compartment model with first order input 
and a one-compartment model with zero order input (71). The 
equations for the zero order model are shown with their derivations 
in the pharmacokinetics section of Appendix 2 (equations 5, 9, 11 & 
12). The coefficients of determination (C^ )^ were examined in 
order to compare the models since both models used an equal number of 
parameters. The coefficient of determination is the ratio of the 
explained variation (total - residual sum of squares, TSSQ - RSSQ) to 
the total variation (TSSQ), i.e.
TSSQ - RSSQ
TSSQ
The model with the higher was considered to give the better 
fit (150).
For the zero order model, estimates of clearance/bioavailability, 
volume of distribution/bioavailability and time to maximum 
concentration (Cl, and t^^) were obtained for each subject, 
for both the acute and chronic data. Paired comparisons of the 
parameter estimates obtained for the acute and chronic days were made 
by the Wilcoxon matched pairs test.
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The acute and chronic data were then fitted simultaneously for each 
subject, giving combined estimates of the parameters. Comparison of 
parameter values between dose levels was made by Kruskal-Wallis 
one-way analysis of variance of ranks.
Plasma S-9780 concentrations from pre-dose samples on days 1 to 8 
were used to estimate the time to reach steady state. An exponential 
function, [0] = A.(1 - e was fitted to the data, allowing the
half-life to reach steady state to be calculated (half-life = 0.693/a); 
it was assumed that it takes between five and seven half-lives to 
reach steady state.
The area under the curve for subjects taking 4 mg daily was 
calculated from dose/clearance for subsequent comparison with data 
from the intravenous study at the same dose. Four mg was chosen 
simply because this was the dose which was common to both studies.
Kinetic analysis after intravenous S-9780
For each subject, the data from the three administered doses were 
fitted simultaneously by extended least squares nonlinear regression 
analysis (160,161,180,196) to several models. This method includes 
weighting as an extra parameter of the model and thus obviates the 
need for prior assumptions about the variance of the data. Ordinary 
least squares analysis was rejected for the intravenous data in view 
of the considerably greater range of drug concentrations which were 
measured and the complex relationship between the variance of the 
assay and the drug concentration (Table 1). The adequacy of each 
model tested was assessed by use of the -2 log likelihood. This 
makes an allowance for the different weighting schemes which may be
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used when comparing models. The difference between the -2 log 
likelihood values for two models follows the Chi-squared 
distribution, with degrees of freedom equal to the difference in 
number of parameters used in the two models (180).
The equations used took the following general form, with one 
exponential term for each compartment (72):
[C] = D.(A.e"*t + B.e'^t + C.e"^^)
where [C] is the plasma concentration of S-9780 in ng.ml”*' 
D is the dose in mg
t is time in hours
A, B and C have the units ng.ml  ^ per mg dose 
or, ji and Y have the units hr ^
The area under the curve was calculated for the 4 mg dose from the 
equation, AUG = 4. (A/a + B/)3 + C/Y) • Since the molecular weight of 
S-9780 is less than that of perindopril, the appropriate conversion 
factor of 1.3 was used when comparing the areas from oral and 
intravenous data.
7.3 RESULTS 
Oral perindopril
The data fitted best the one-compartment model with zero order input 
The model comparisons for the subjects taking 16 mg daily are shown 
in Table 19. This was the dose at which the peak concentrations
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Zero o rd e r F i r s t  o rd e r
Subj TSSQ RSSQ % TSSQ RSSQ
31 1926 104 0.946 .1929 405 0.790
32 1935 60 0.969 1957 180 0.908
33 889 8 0.991 918 67 0.927
34 2258 280 0.876 2260 547 0.758
35 1722 31 0.982 1671 137 0.918
36 407 24 0.941 395 17 0.957
Table 19. Model comparison for pharmacokinetics of S1-9780 after 16 mg
of perindopril orally: total sum of squares (TSSQ), residual sum of
squares (RSSQ) and coefficient of determination (Cd ) . For
both models, the number of parameters was 3 and the degrees of freedom
were 5.
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occurred latest and for which there was greatest reason to test the 
alternative model. The one-compartment model with zero order input 
was used to estimate the following results.
The parameter estimates obtained from the separate fits of acute and 
chronic data are shown in Table 20. The estimates of clearance and 
volume of distribution were not significantly different after 
repeated dosing to those after the first dose.
Estimates of the same parameters from the simultaneous fitting of the
acute and chronic data are shown in Table 21. Clearance/
bioavailability and volume of distribution/bioavailability were not
dose dependent although the time to peak concentration (t^^ )^
increased with dose. The measured serum concentration v time
profile and the fitted curve for a representative subject are shown
in Figure 14. The mean area under the curve from 0 to œ  for subjects
-1
given 4 mg of perindopril was 94.5 + 15.5 ng.ml .hr. Time to 
reach steady state was estimated to be 43 - 60 hours (Figure 15).
Intravenous S-9780
The model comparisons are shown in Table 22. The three-compartment 
model clearly offered a better fit for all subjects than either of 
the reduced models. There was no justification for using a four 
compartment model. The results which follow were obtained using the 
three-compartment model.
The estimates obtained for the parameters are shown in Table 23. The 
average half-lives derived from these parameters were 0.2 + 0.04 
hours for the first phase, 1.24 + 0.2 hours for the second phase and
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Acute data only Chronic data only
)Ubj Dose Cl '^ D tmax s Cl "d
tmax CD
mg
-1
l.hr 1 hr l.hr 1 hr
9 4 39.8 337 0.10 0.933 31.6 215 1.17 0.979
10 4 77.2 389 0.11 0.910 43.8 274 0.63 0.993
14 4 41.9 222 0.005 0.986 39.3 236 0.001 0.977
15 4 60.3 247 2.03 0.997 35.1 184 1.24 0.981
17 4 36.9 226 0.01 0.942 34.6 268 0.00 0.919
18 4 42.4 296 0.93 0.974 40.5 252 0.22 0.986
19 8 50.2 488 2.47 0.922 50.3 595 1.33 0.969
21 8 21.7 110 2.88 0.932 20.2 92 3.12 0.957
25 8 38.1 104 5.47 0.944 42.8 230 2.03 0.768
26 8 32.2 181 2.87 0.959 30.4 134 2.90 0.988
28 8 64.4 497 1.41 0.962 48.0 555 1.70 0.984
30 8 44.8 406 0.12 0.954 42.3 421 0.95 0.972
31 16 42.4 276 4.00 0.946 49.6 294 3.07 0.979
32 16 41.8 239 3.00 0.969 47.9 309 2.42 0.885
33 16 44.4 377 3.58 0.991 38.7 321 1.19 0.977
34 16 37.7 285 2.19 0.876 45.4 368 2.74 0.852
35 16 43.2 249 3.34 0.982 37.9 271 2.38 0.983
36 16 63.9 559 3.48 0.941 57.0 580 2.19 0.986
Table 20. Parameter estimates from separate fitting of acute (n = 9) and
chronic (n = 9) S-9780 data after oral perindopril: clearance/
bioavailability (Cl), volume of distribution/bioavailability (V^),
time to peak concentration (t ) and coefficient of determination (C^).
max D
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Combined acute and chronic data
Subj Dose Cl t
max Cd
- 1
mg l.hr 1 hr
9 4 37.6 308 0.41 0.93
10 4 58.4 369 0.02 0.91
14 4 40.6 229 0.01 0.98
15 4 45.4 238 1.55 0.91
17 4 35.8 240 0.01 0.93
18 4 42.6 278 0.62 0.98
19 8 53.6 507 2.31 0.90
21 8 21.1 102 2.99 0.94
25 8 37.2 200 2.50 0.73
26 8 32.1 162 2.90 0.96
28 8 54.1 537 1.51 0.94
30 8 44.1 422 0.69 0.96
31 16 47.9 274 3.94 0.92
32 16 43.9 260 2.72 0.92
33 16 42.3 331 2.49 0.77
34 16 41.2 321 2.40 0.80
35 16 40.8 265 2.84 0.96
36 16 61.9 583 2.78 0.93
Table 21. Parameter estimates for S-9780 data after oral perindopril;
acute and chronic data fitted simultaneously (n = 18): clearance/bio­
availability (Cl), volume of distribution/bioavailability (V^), time
to peak concentration (t ) andcoefficient of determination (C_J.max D
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1-compartment 2-compartment 3-compartment 4-compartment 
Subj -2 log. like. -2 log. like. -2 log. like. -2 log. like.
1 466 442 313 * 313
2 484 434 336 * 336
3 327 301 235 * 235
4 514 464 373 * 373
5 350 317 238 * 235
6 504 448 331 * 331
7 497 447 331 * 331
8 517 517 356 * 356
Table 22. Comparison of models for S-9780 pharmacokinetics after 
intravenous dosing. As adjacent models differ by two parameters, 
the critical difference for -2 log. likelihood values at p < 0.05 
is 6.0; * represents the best model.
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Subject A a B C V terminal
half-life
-1
ng.ml hr-1
-1
ng.ml hr-1
-1
ng.ml hr"1 hr
per mg per mg per mg
1 110 6.2 63 0.70 2.5 0.062 11 .99
2 110 3.1 52 0.49 1.0 0.017 41 .98
3 70 4.1 82 0.70 1.0 0.020 34 .98
4 100 3.3 70 0.51 1.3 0.018 38 .96
5 120 3.2 59 0.51 0.4 0.012 60 .99
6 110 3.0 66 0.47 1.0 0.017 41 .97
7 80 3.9 79 0.68 2.4 0.053 13. .98
8 120 3.0 78 0.54 1.6 0.053 13 .96
mean 100 3.7 68 0.58 1.5 0.040 31
SD 20 1.1 10 0.10 0.7 0.026 17
Table 23. Pharmacokinetic parameters derived from intravenous S-9780 
data (n = 51) fitted to a 3-compartment model,
[C] = Dose.(A.e ^  + B.e + C.e represents coefficient
of determination.
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31.4 + 17.5 hours for the terminal phase. Data and fitted curves for 
one subject are shown in Figure 16. The average area under the curve 
calculated for the 4 mg dose in the eight subjects was 
822 + 125 ng.ml \hr.
Comparison of the area under the curve after oral perindopril with 
the area after intravenous S-9780, 94.5 _v 822 ng.ml \hr, gives an 
estimate of bioavailability for S-9780 of 15%.
7.4 DISCUSSION
The intravenous data were best fitted by a three compartment model 
This is consistent with the findings after studies with radiolabelled 
S-9780 in animals (Institut de Recherches Internationales Servier: 
personal communication). Also in general agreement with those 
results in animals (Appendix 1) are the estimates of half-lives 
obtained from this study although this study may have underestimated 
the terminal half-life: in retrospect, additional samples taken
between 8 and 48 hours, and possibly beyond 48 hours, would have been 
useful. Even so, the terminal half-life is relatively long (over 30 
hours) and this figure is not dissimilar to the estimates of 35 to 38 
hours which have been quoted for another inhibitor of angiotensin 
converting enzyme, enalaprilat (94,203).
Despite the apparently slow elimination of enalaprilat. Till et al 
(197) have demonstrated that steady state enalaprilat levels are
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Figure 16. Plasma S-9780 concentrations in one subject following 
1 mg ( X ), 2 mg ( 0  ) and 4 mg (□) of S-9780 intravenously, with the 
fitted curves from a three-compartment model.
reached within 30 - 60 hours in normal volunteers. They propose that 
some form of enalaprilat binding delays excretion of a small pool of 
drug; but this does not influence excretion of free drug or delay the 
attainment of steady state. A similar mechanism is likely to exist 
for S-9780. The data from the perindopril oral dosing study support 
this hypothesis: steady state appears to be reached after 43 - 60
hours, which is considerably less than the 150 - 210 hours which 
might be anticipated from a terminal half-life of 31 hours.
The pharmacokinetics of S-9780 do not appear to vary significantly 
with dose. After oral perindopril 4 - 1 6  mg, the values obtained for 
clearance and volume of distribution of S-9780 were equal for each 
dose. It appears that the pharmacokinetics are linear. Simultaneous 
fitting of data from the three doses of intravenous S-9780 appears 
justified. The satisfactory fits obtained also support the method 
used.
Finally, it is not possible to calculate with certainty the 
bioavailability of S-9780 from oral and intravenous data obtained in 
separate groups of subjects. Nevertheless, the age range, sex and 
weights of the subjects in the two groups did not differ and the 
clinical and laboratory conditions of the studies were identical.
The main source of error in any comparison is likely to be the 
difference in the kinetic models which were fitted: after oral
dosing the one-compartment model will tend to underestimate the tail 
of the curve. The figure obtained for bioavailability of 15% is 
unlikely to be widely inaccurate, however, and it provides a useful 
estimate for the design of future studies involving intravenous 
administration of S-9780.
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The angiotensin converting enzyme inhibition curves which were 
obtained after perindopril and S-9780 support the assumption that the 
bioavailability is relatively low, since 1 mg of S-9780 given 
intravenously produced inhibition of similar degree to 8 and 16 mg of 
perindopril orally and higher intravenous doses of S-9780 did not 
cause any further inhibition.
In conclusion, this study has demonstrated that S-9780 data after 
intravenous administration fit a conventional three-compartment 
model, giving an estimated terminal half-life of 31 hours. The data 
from oral dosing with perindopril suggest that bioavailability is 
relatively low at about 15%, that the pharmacokinetics of S-9780 are 
linear within the range studied, and that repeated dosing with 
perindopril for one week does not cause significant changes in S-9780 
disposition. Despite the apparent long elimination half-life of 
S-9780, steady state is reached in healthy volunteers after 43 - 60 
hours.
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CHAPTER 8
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PHARMACODYNAMICS OF S-9780
8.1 INTRODUCTION
For certain drugs, notably theophylline, digoxin and the 
anticonvulsants, a therapeutic range of plasma concentrations has 
been defined and can be used in conjunction with plasma concentration 
measurements in patients to aid in the selection of a suitable dosage 
regimen for the individual. Where the effect of a drug can be 
quantified, it may be possible to define the concentration-effect 
relationship for that drug in an individual subject. If that 
relationship can be shown to be predictable and to persist after 
chronic treatment, such information may allow the selection of an 
appropriate long-term dose when the response to acute treatment is 
known.
Brunner (26) has suggested that the response of healthy volunteers 
to inhibitors of angiotensin converting enzyme allows prediction of 
the therapeutic effects in patients. He has suggested that new 
angiotensin converting enzyme inhibitors might be developed almost 
exclusively in normal volunteer studies and that the effects might be 
extrapolated to patients with the aid of only limited further 
studies. Such a procedure would probably accelerate the development 
of new compounds, since the recruitment of suitable patients often 
appears to be the rate-limiting step in clinical trials.
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Experimental work with animals has established the relationship 
between S-9780 concentration and inhibition of angiotensin converting 
enzyme in vitro (116). The pharmacokinetics of S-9780 in man 
have been demonstrated in Chapter 7 to be comparable to the pharmaco­
kinetics in animals. If full weight is to be placed on the safety 
and tolerance information which is available from animal work, then 
it is also necessary to demonstrate the relevance of the vitro 
results by studying the relationship between drug levels and effects 
in man.
This study seeks to determine the relationship between plasma S-9780 
concentration and angiotensin converting enzyme inhibition after oral 
dosing with perindopril and after direct intravenous administration 
of S-9780 in healthy subjects. The possibility of predicting 
response at steady state is also addressed.
8.2 METHODS
Details of the protocols, laboratory methods and both the 
pharmacokinetics and the dynamic results of the studies in healthy 
volunteers after oral perindopril and intravenous S-9780 have been 
given in preceding chapters (2, 3, 4 & 7).
Pharmacodynamics after intravenous S-9780
The plasma angiotensin converting enzyme inhibition data from the 
study of the effects of intravenous S-9780 were related directly to 
the plasma concentrations of S-9780, measured on the same sample, 
using the Hill equation (111):
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where [C] is plasma S-9780 concentration, [C^^] is the concentration 
of S-9780 which produces 50% inhibition of plasma angiotensin 
converting enzyme and V gives a measure of the sigmoidicity of the
relationship. Separate fits were obtained for each subject using
nonlinear ordinary least squares regression analysis (134). Results 
are quoted along with the coefficient of determination (C^), 
which shows the fraction of the variation in the data which is 
explained by the model (150).
Pharmacodynamics after oral perindopril
The results obtained for inhibition of plasma angiotensin converting 
enzyme and plasma S-9780 concentrations after oral treatment with 
perindopril suggested that the relationship between drug 
concentration and effect was not simply sigmoidal (Figure 17). It 
appeared that the response was out of phase with the drug 
concentration, a situation which can be demonstrated by the 
occurrence of hysteresis when the response is plotted against drug
concentration. This is shown for one subject in Figure 18.
In order to relate the response profile to the drug concentration 
profile, a model was used which included a term describing 
the disequilibrium between the two profiles. The pharmacokinetic 
model from Chapter 7 which described the S-9780 plasma concentrations 
after oral perindopril was modified for this purpose.
The pharmacokinetic model was itself unchanged but a second 
compartment relating to the pharmacodynamics was postulated, deriving
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Figure 17. Mean plasma angiotensin converting enzyme inhibition data 
following oral perindopril, from Figure 4, and plasma S-9780 
concentrations in a single subject after 4 mg perindopril orally, 
from Figure 14: a difference in the profiles is evident.
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Figure 18. Plasma angiotensin converting enzyme inhibition data 
plotted against plasma S-9780 concentration in a single subject 
following perindopril 4 mg orally: a hysteresis effect is
demonstrated, confirming that the two profiles are out of phase.
drug from the central compartment by a first order process. 
Elimination from the second, ’effect’, compartment was also governed 
by first order pharmacokinetics. Such a model has been described by 
Sheiner _ e ^ (181) and is displayed in Figure 19. The concept 
has been further discussed by Whiting and Kelman (218). The 
equations which were used and their derivations are given in the 
pharmacodynamics section of Appendix 2 (equations 15, 17 & 18).
The pharmacokinetic parameters from Chapter 7 were used to predict 
S-9780 concentrations in the effect compartment, [C^], at each of 
the times of angiotensin converting enzyme sampling. The plasma 
angiotensin converting enzyme inhibition data were then fitted to 
these concentrations by nonlinear regression analysis (134), once 
again using the Hill equation. Thus, in this case a further 
parameter was estimated: keq, the rate constant describing the
disequilibrium between drug in the plasma and the effect profiles.
The data from acute and chronic studies were fitted separately using 
the combined pharmacokinetic values. Reduced models were then 
investigated by constraining each of the three parameters (keq, 
and Y) in turn to be common to both data sets. Finally, further 
comparisons were made when two or three parameters were common to 
both days. For models with equal degrees of freedom, the one which 
minimised the residual sum of squares was chosen as more appropriate; 
otherwise, the general linear test (150) was used to compare the 
models. Comparisons between parameter estimates were made by the 
Wilcoxon matched pairs test.
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Figure 19. Diagrammatic representation of a one-compartment kinetic 
model with an ’effect’ compartment which does not influence the 
kinetics but allows for a disequilibrium between plasma concentration 
of drug and inhibition of angiotensin converting enzyme.
8.3 RESULTS 
Intravenous study
The inhibition of plasma angiotensin converting enzyme following
intravenous administration of S-9780 was closely related to observed
drug concentration, with 74% - 94% of the variation in inhibition
being explaind by the drug concentration data. Average values
obtained from the Hill equation for V and [C^.] were 0.75 + 0.16
50
and 1.8 + 0.9 ng.ml  ^ respectively. The individual parameters 
are shown in Table 24 and the data from one subject are shown with 
the fitted curve in Figure 20.
Oral study
For only two out of the eighteen subjects could the full model, where 
none of the parameters was common to both data sets, be shown to give 
a better fit than the model which constrained V to be common to both 
days. The latter model was also shown to fit the data as well as or 
better than any of the other models for the majority of the eighteen 
subjects. The model comparisons are shown in Table 25.
For all subjects, keq was found to increase after chronic treatment,
although in five cases the exact value of the parameter could not be
determined due to variation in the data. For the remaining thirteen
_ 1
subjects, the average value of keq increased from 0.22 + 0.2 hr 
for the acute dose to 0.63 + 0.6 hr  ^ for the chronic dose 
(p < 0.001). The mean for the eighteen subjects
increased from 1.6 + 1.1 ng.ml to 2.7 + 2.6 ng.ml (p < 0.01).
The mean value of F, which was common to both days, was 
0.83 + 0.46. The individual parameter estimates are shown in
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Subject
ng.ml-1
degrees of 
freedom
0.92
0.59
0.53
0.85
0.70
0.98
0.74
0.68
1.2
0.7
1.1
1.4
3.1
2.9
1.9
2.2
0.85
0.81
0.74
0.92
0.82
0.94
0.82
0.91
49
48 
32
49 
32 
48
48
49
mean
SD
0.75
0.16
1.8
0.9
Table 24. Estimates of parameters from the Hill equation 
after fitting angiotensin converting enzyme inhibition to 
S-9780 concentrations.
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Full model
RSSQ
V common
RSSQ RSSQ 'D
9 4 18 1053 0.91 1445 * 0.88 2864 0.75
10 4 18 516 0.92 670 * 0.90 690 0.89
14 4 18 710 0.93 853 0.91 735 * 0.92
15 4 16 192 0.96 192 * 0.96 1810 0.62
17 4 18 1670 0.86 1746 0.85 1732 * 0.86
18 4 18 632 0.94 671 * 0.94 679 0.93
19 8 17 722 0.84 876 0.81 772 * 0.91
21 8 18 160 0.98 166 * 0.97 660 0.90
25 8 18 413 0.95 424 0.95 424 0.95
26 8 18 599 0.92 627 * 0.92 685 0.91
28 8 18 163 0.98 510 0.94 227 * 0.97
30 8 18 146 0.98 248 0.96 167 * 0.97
31 16 18 497 0.95 652 * 0.93 701 0.92
32 16 18 254 0.97 267 * 0.97 285 0.96
33 16 18 243 0.96 303 * 0.96 344 0.95
34 16 18 60 0.99 60 * 0.99 71 0.99
35 16 18 410 0.96 446 * 0.96 681 0.94
36 16 18 122 0.98 129 * 0.98 135 0.98
Table 25. Model comparisons for concentration-effect relationship 
after oral perindopril: residual sum of squares (RSSQ) and co­
efficient of determination (C^). The model which appeared to 
give the best fit is marked by *. The full model had 12 degrees of 
freedom and the reduced models had 13, thus a higher for the 
full model does not necessarily imply a better fit; the general 
linear test was used to test for this (150).
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Table 26 and the time course for inhibition from one subject is shown 
with the fitted curves in Figure 21.
8.4 DISCUSSION
This study has demonstrated that the plasma concentration of S-9780 in 
vivo which produced 50% inhibition of plasma angiotensin converting 
enzyme was 1.8 + 0.9 ng.ml"^ (mean + SD). In vitro work with 
guinea pig plasma gave an 10^^ for S-9780 of 0.82 + 0.03 ng.ml  ^ (116). 
After acute oral dosing with perindopril, the concentration of S-9780 
in the ’effect' compartment which produced 50% inhibition of plasma 
angiotensin converting enzyme was 1.6 + 1.1 ng.ml
There is an apparent disparity between the need to use an 'effect 
compartment' in order to fit the angiotensin converting enzyme 
inhibition data to S-9780 concentrations following oral dosing with 
perindopril and the satisfactory direct correlation which was 
obtained between plasma S-9780 concentrations and enzyme inhibition 
following intravenous administration of S-9780. The values obtained 
for [C^q ] after acute intravenous dosing and for after acute
oral dosing are not dissimilar and are particularly low relative to 
the concentrations of S-9780 achieved after intravenous dosing.
Thus, the S-9780 concentrations in the intravenous study produced 
values for percentage inhibition of angiotensin converting enzyme 
which lay in a narrow range near the maximum possible. The 
sensitivity of measuring changes in inhibition within that range is 
low.
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ubj Dose
mg
keq^
hr"1
y ^^50^a
-1
ng.ml
keq^
hr"''
^^50^c
-1
ng.ml
CX^(O)]
-1
ng.ml
^D
9 4 0.18 1.42 2.9 0.53 7.0 0.0 0.88
10 4 0.23 0.59 1.2 0.25 1.0 0.7 0.90
14 4 0.08 1.72 3.0 0.12 3.4 2.3 0.91
15 4 0.06 1.23 2.3 0.21 9.6 3.0 0.96
17 4 0.06 1.61 2.5 0.23 4.0 1.9 0.85
18 4 0.14 1.42 2.6 0.36 3.9 3.8 0.94
19 8 0.06 0.63 4.0 0.19 5.5 7.4 0.81
21 8 1.66 0.29 1.1 >5 3.1 0.1 0.97
25 8 0.39 0.42 0.7 0.79 0.7 0.1 0.95
26 8 0.26 0.47 0.5 >5 0.9 3.6 0.92
28 8 0.01 0.72 0.1 0.23 0.6 0.8 0.94
30 8 0.08 0.35 0.1 2.20 0.5 2.0 0.96
31 16 0.32 0.73 1.1 0.79 0.5 2.2 0.93
32 16 0.74 0.48 0.6 1.42 0.8 0.9 0.97
33 16 0.42 0.34 0.2 >5 0.4 1.2 0.96
34 16 1.22 0.87 1.3 >5 2.0 5.3 0.99
35 16 0.22 0.91 2.0 >5 3.6 3.2 0.96
36 16 0.56 0.86 1.7 0.85 1.5 2.4 0.98
Table 26. Effect parameters following oral dosing with perindopril, 
fitting one-compartment pharmacokinetics (combined for acute (a) and 
chronic (c) days) constraining y to be common to both days but allowing 
keq and [Cg^^] to vary between days; [X^(0)] represents the 
drug concentration in the effect compartment at the time of the seventh 
dose and represents coefficient of determination, n = 18.
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As a test of the above explanation, the angiotensin converting enzyme 
inhibition data from the study of intravenously administered S-9780 
were compared with the predicted data from an effect model which used 
the known intravenous pharmacokinetics along with the parameter estimates 
obtained from the oral dynamics. The predicted curves were quite 
dissimilar to the actual data. Thus, if a phase difference between 
plasma drug concentration and effect also existed after intravenous 
administration then it should have been apparent under the conditions 
of the study.
Nevertheless, at the level of plasma concentrations of 3-9780 which 
was achieved after oral dosing with perindopril, there was greater 
sensitivity in the measurement of inhibition of angiotensin 
converting enzyme. A clear phase difference existed between the 
concentration _v time profile and the effect 2 time profile. That 
difference is described mathematically by the model used. Lack of 
specificity of the assay for S-9780 would explain such a phase 
difference; parent drug might have been activated during the early 
stages of the assay. The careful checks on specificity which were 
made (Chapter 2, section 5) appear to preclude this explanation.
The value obtained for V of 0.83 + 0.46 suggests that the Langmuir 
equation might have been adequate to fit the data: it represents
a special case of the Hill equation, where V is equal to one. The 
fuller equation makes no a priori assumption about the sigmoidicity 
of the relationship.
The purpose of effect modelling is to use data obtained from acute 
dosing studies to predict the effect which will be achieved at steady
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State. The results obtained after oral perindopril in normal 
volunteers show, however, that the two parameters, and
keq, increase after repeated dosing. These increases are effectively 
describing a reduced sensitivity to similar drug concentrations after 
chronic exposure and more rapid onset and offset of action. No 
difference in S-9780 pharmacokinetics occurs to explain this observation 
(Chapter 7). There were insufficient data from this study to 
establish how long it took for the change in responsiveness to occur.
It is not clear whether the alteration occurs in a gradual and 
progressive manner or whether some qualitative change takes place 
after the first exposure to the drug. Because of these findings, 
prediction of the effect at steady state may not be possible from 
acute studies.
An increase in might be accounted for by either of two
mechanisms. The binding of drug to a plasma protein to provide an 
inactive plasma pool may occur, thus causing total plasma drug 
concentration measurement to overestimate the concentration available 
for inhibition of angiotensin converting enzyme. The long terminal 
half-life of the drug (Chapter 7) is consistent with protein binding.
The binding protein cannot be plasma angiotensin converting enzyme, 
however, as suggested by Till ^  ^  (197), since no increase in 
[Cg^g] should then occur.
The alternative mechanism also provides an explanation for the 
observed increase in keq. Induction of plasma angiotensin converting 
enzyme may occur with repeated dosing, such that the expression of 
the enzyme activity after chronic dosing as a function of the 
pretreatment values results in spurious underestimates of inhibition.
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Unfortunately, expression of the activity in other ways does not help 
to avoid the problem. Induction of angiotensin converting enzyme has 
been reported in animals (65) and has been shown to be a possibility 
in man (63).
If the latter mechanism holds, then a rebound rise in angiotensin 
converting enzyme activity might be anticipated following withdrawal 
of the drug. This has not been reported and was not seen in the 
studies examined here. The slow elimination of the drug may, 
however, be sufficiently gradual to allow homeostatic mechanisms to 
curtail excess enzyme production as drug levels fall and to prevent 
any rebound. Measurement of total angiotensin converting enzyme 
protein rather than activity would help to answer the question.
The extrapolation of effects on angiotensin converting enzyme to 
antihypertensive activity remains an area which is fraught with 
problems. The relationship between the two effects has been shown to 
be close in some studies (104,170) but other work suggests the 
converse (211). Blood pressure falls in normotensive subjects tend 
to be small and the variation large. Satisfactory modelling of blood 
pressure responses to drug concentration or to inhibition of plasma 
angiotensin converting enzyme in these subjects is therefore 
difficult; a similar approach using data from hypertensive patients 
may prove more productive.
In conclusion, evidence is provided that the plasma concentration of 
S-9780 which produces 50% inhibition of plasma angiotensin converting 
enzyme after acute dosing is 1.8 + 0.9 ng.ml  ^ (mean + SD).
Whilst inhibition of plasma angiotensin converting enzyme is
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sigmoidally related to plasma drug concentrations after acute 
intravenous administration, the concentration-effect relationship 
following oral administration of the parent compound is complex. 
Repeated dosing with perindopril causes apparently diminished 
sensitivity of plasma angiotensin converting enzyme to equivalent 
concentrations of S-9780. This provides further evidence that human 
plasma angiotensin converting enzyme may be induced by prolonged 
inhibition.
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CHAPTER 9
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GENERAL DISCUSSION AND CONCLUSIONS
9.1 DISCUSSION
In the background discussion (Chapter 1) it was suggested that, 
despite the wide range of antihypertensive agents already available, 
there was still scope for new agents to be investigated, particularly 
in classes of drug which were not already over represented. The aims 
of testing such new drugs were to seek a treatment which was widely 
tolerated, safe, effective and compatible with established regimes.
The clinical pharmacology of two recently available antihypertensive 
agents, captopril and enalapril, was discussed. The efficacy of 
these drugs in hypertension and congestive heart failure is 
established and there is increasing evidence of their compatability 
with other treatments. Information concerning the safety of the 
drugs suggests that they are generally well tolerated but not 
entirely free from side effects or toxicity. Thus, there was 
justification for studying a further member of this class of drugs. 
Initial data on efficacy and safety of perindopril from animal
studies (Appendix 1) was encouraging.
Before strict clinical comparisons between perindopril and the 
established compounds could be undertaken, the tolerability, safety 
and basic clinical pharmacology of perindopril had to be confirmed in
man. The studies described in this thesis set out to determine that
information.
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It was acknowledged in Chapter 1 that the testing of new compounds in 
man requires rigorous attention to safety and ethical considerations. 
It was also accepted that the breadth of information which is 
required for each new compound is such that multiple studies are 
needed to collect the necessary data.
In selecting the design of the early studies, a compromise had to be 
reached. The number of subjects who were exposed to the new compound 
had to be limited but the maximum information had to be gained and 
the results had to be sufficiently clear to let the data form the 
premises for major decisons regarding the design of further 
investigations.
The dose-ranging study with orally administered perindopril 
(Chapter 3) provides an example of the successful application of such 
a compromise. Initially, only two subjects at a time were studied, 
with low doses of the drug, and were intensively monitored. The 
hormonal effects were measured as treatment continued and the study 
could have been terminated at any stage if any untoward effect 
occurred. The number of subjects studied at each dose was expanded 
after a higher dose had been found to be tolerated and in this way a 
profile of activity was obtained at a variety of doses.
As the study progressed it appeared that the likely therapeutic dose 
of perindopril was about 8 mg. Since an open study is not the ideal 
design for assessing subjective symptoms or effects on blood 
pressure, a double-blind, randomised comparison of 8 mg of 
perindopril and placebo was included.
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The detailed information obtained from the study confirmed the 
activity of perindopril in man, provided evidence of its tolerability 
and safety after treatment for one week in 30 subjects and suggested 
a suitable dose for future study.
Studies of the effects of the angiotensin converting enzyme 
inhibitors on haemodynamics in heart failure are more practically 
carried out using acute intravenous administration than oral dosing. 
Since such patients may sometimes be sensitive to small doses of an 
angiotensin converting enzyme inhibitor, it was necessary to 
establish the safety and efficacy profile of an intravenous 
formulation early in the course of the investigations. Once again, a 
dose-ranging study was chosen but, since repeated dosing was not 
intended, a double blind crossover design was suitable with dose 
order determined by reference to a latin square. This provided a 
study with greater power than a parallel study of similar size.
The discovery that the inhibition of angiotensin converting enzyme 
was equal with all three doses studied was unexpected. The doses had 
been chosen in the light of the results of the oral study with 
perindopril and expected bioavailability of over 50%; the 
bioavailability of enalaprilat is approximately 60% following oral 
enalapril administration (203). This information will be 
particularly valuable in the choice of dose for future studies.
There would be no justification for exceeding 1 mg of S-9780 
intravenously. As with the oral dose-ranging study, the tolerability 
and safety profile of S-9780 appeared good.
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The oral dose-ranging study with perindopril left unanswered the 
question of whether perindopril lowered blood pressure in normal 
volunteers at a dose of 8 mg. It also raised the question of whether 
perindopril might cause tachycardia, in contrast to the widely 
reported effects of other inhibitors of angiotensin converting 
enzyme (88,143,151). A study of the blood pressure response and 
autonomic effects of perindopril was designed to examine these 
points. A larger number of subjects was recruited and a double-blind 
crossover design was employed, with the intention of increasing the 
power of this study relative to the earlier work.
The questions were answered. Perindopril had effects which were 
consistent with those of enalapril and captopril on both counts.
Thus, there were grounds for believing that the effects of 
perindopril on the renin-angiotensin system and the blood pressure 
were similar to those of captopril and enalapril. Full studies of 
the safety and efficacy in patients could not be undertaken without 
evidence of the effects of longer periods of treatment than one week 
and of the response in hypertensive patients. This group might be 
expected to show greater sensitivity to the drug than normal 
volunteers.
A study of one month’s treatment with perindopril in hypertensive 
patients was designed. Since it was wished to limit once again the 
number of patients exposed to the drug and to gain the knowledge of 
its effects within a reasonable period of time, the patients were 
used as their own controls. The statistical analysis took account, 
as far as is possible, of the inevitable downward trend in blood
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pressure over the course of the trial, part of which was unrelated to 
treatment. The results of the study showed that the drug was well 
tolerated for longer periods of treatment, that it was effective as 
an antihypertensive agent and that it appeared to be safe in this 
group of patients.
The next stage in the investigation was to commence a long-term and 
larger scale comparison of perindopril with established treatment. 
This is currently in progress locally, in collaboration with 
colleagues in general practice.
The dose-ranging studies in normal volunteers permitted the 
collection of extensive data regarding the pharmacokinetics of S-9780 
after direct intravenous administration of S-9780 and afer oral 
administration of perindopril.
It was reassuring to find that after intravenous dosing the kinetics 
of the metabolite, S-9780, correspond closely in man to the kinetics 
in the animals which were used for preclinical toxicological studies. 
Any difference which was present would tend to diminish the transit 
time in man.
Of some concern to clinicians was the observation that the terminal 
half-life of enalaprilat exceeded 35 hours in normal subjects. If 
that half-life was representative of elimination of drug from the 
body then accumulation would be anticipated over many days following 
inception of therapy. A half-life of over 30 hours was also found 
for perindopril (Chapter 7) but the data from the oral dosing study 
allowed the accumulation half-life to be estimated at under 9 hours.
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This figure is much more consistent with the observed time course of 
the effect than the higher estimate. It also supports the work of 
Till _et ^  (197), suggesting accumulation of enalaprilat ceases after 
2 to 3 days in normal subjects.
The relationship between the plasma concentration of a drug and its 
dynamic effect is a field of increasing interest and potential 
practical application. In Chapter 8, this relationship has been 
explored for S-9780 after acute intravenous administration, when the 
effect is clear and easily understood, and after repeated oral 
administration of perindopril. In the latter case, a fascinating 
question has been raised but not answered.
It is difficult to explain why a drug which in vitro and, after 
intravenous infusion, in vivo appears to cause immediate inhibition 
of plasma angiotensin converting enzyme should produce similar 
inhibition vivo following ordinary administration of perindopril 
only after a significant delay has occurred. It should be noted that 
drug concentration and angiotensin converting enzyme activity were 
measured on the same samples. These were stored at -20°C before 
analysis. There was, therefore, ample time for in vitro 
equilibration to proceed.
If the assay for S-9780 was not specific to the metabolite then 
spuriously high levels of drug would be measured soon after dosing 
which would cause the apparent phase difference. The available 
information does not support this explanation, particularly as the 
drug is measured on the basis of its inhibitory activity. An 
inactive metabolite or pro-drug which was separated from plasma along
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with the S-9780 would not register in the angiotensin converting 
enzyme inhibition stage of the assay.
Conversion of perindopril to S-9780 is promoted by rat plasma. The 
assay system used rabbit plasma, which does not significantly 
hydrolyse perindopril, and specificity for S-9780 was confirmed.
If the hysteresis effect had been present for only one or two 
subjects then it might reasonably have been attributed to biological 
variation. The effect was consistent for all eighteen subjects after 
the first dose, however. A change in the concentration-effect 
relationship was shown after repeated dosing and an explanation for 
the change is advanced.
Further study of the concentration-effect relationships with 
perindopril and with other inhibitors of angiotensin converting 
enzyme should prove interesting in this regard.
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9.2 CONCLUSIONS
The main conclusions from the studies described in this thesis are as 
follows;
1 That perindopril was well tolerated by over fifty subjects
treated for periods of up to one month, with no evidence of 
biochemical or haematological toxicity.
2 That the diacid metabolite of perindopril, S-9780, is a potent
and long-acting inhibitor of plasma angiotensin converting 
enzyme in humans, with predictable and dose-related effects on 
the renin-angiotensin system.
3 That perindopril 8 mg orally possesses useful blood pressure
lowering activity without causing tachycardia or postural 
hypotension.
4 That perindopril enhances parasympathetic activity and that
this action is probably a general feature of the angiotensin 
converting enzyme inhibitors.
5 That the pharmacokinetics of S-9780 are linear.
6 That the pharmacokinetics of S-9780 following acute intravenous
administration of S-9780 follow triphasic decay, with a 
terminal half-life of 30 hours.
7 That the accumulation half-life of S-9780 after oral
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administration of perindopril is under 9 hours and that steady 
state is achieved in 43-60 hours.
8 That the oral bioavailability of S-9780 is low, probably about 
15%.
9 That the concentration of S-9780 which causes 50% inhibition of
plasma angiotensin converting enzyme in vivo is 1.8 + 0.9 ng.ml  ^
(mean + SD) for man.
10 That the concentration-effect relationship between S-9780 and
angiotensin converting enzyme inhibition is complex following 
oral administration of perindopril but that changes occur after 
repeated dosing which suggest diminished sensitivity to the 
drug.
11 That angiotensin converting enzyme may be induced by prolonged
inhibition.
12 That studies of a new angiotensin converting enzyme inhibitor
in normal volunteers provide useful and relevant information 
about the likely response in hypertensive patients.
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APPENDIX 1
A1.1 STRUCTURE
Perindopril is (2S,3aS,7aS) 1- [(2S) 1- [(IS) 1-ethoxycarbonyl 
butylamino] 1-oxopropyl] perhydroindole 2-carboxylic acid 
terbutylamine salt (Figure 3). It is hydrolysed by esterases in 
vivo to the active diacid form, S-9780.
A 1.2 PHARMACOLOGY*
S-9780, the diacid form of perindopril, inhibited guinea pig plasma 
angiotensin converting enzyme (ACE) by 50% (IC^^) at a concentration 
of 2.4 + 0.1 nM (0.82 ng.ml ^). A of 1.2 nM was obtained 
for S-9780 (Dixon Webb plot) with angiotensin I as a substrate. In 
rabbits, rats, cats, guinea pigs and dogs, S-9780, enalaprilat, 
perindopril and enalapril decreased, in a dose dependent manner, the 
pressor response to angiotensin I. The rabbit and the rat were the 
most sensitive species, with ID^^ values, respectively, of 2.7 + 0.4 
and 5.9 + 0.3 ^g.kg  ^ i.v. for perindopril and 1.2 + 0.2 and 
2.6 + 0.8 ^g.kg  ^ i.v. for S-9780.
Perindopril induced a dose-dependent decrease in serum ACE activity
“ 1 •  1 
in rabbits (0.6 - 20 ^g.kg" i.v.) and guinea pigs (10 - 100 ^ug.kg
i.v.). In conscious rats and dogs perindopril (0.03 - 1 mg.kg  ^ p.o.)
induced a long-lasting inhibition of the angiotensin I-induced
pressor response; 40% inhibition was recorded in dogs, 24 hours
213
-1 -1 
after 1 mg.kg p.o. Perindopril (0.03 - 0.1 mg.kg i.v.)
potentiated the increase in femoral blood flow induced by bradykinin
injected into the femoral artery of dogs.
In anaesthetised dogs, mean blood pressure and heart rate were not 
changed after sodium restriction, but the cardiac output was markedly 
decreased. Perindopril (0.1 - 1 mg.kg  ^ i.v.) decreased mean 
blood pressure both in sodium-restricted and sodium-replete 
pentobarbital-anaesthetised dogs. However, the lowering effect was 
more pronounced in sodium-restricted dogs.
Perindopril (3 mg,kg p.o.) did not change mean blood pressure 
in conscious dogs maintained on normal-sodium diet but decreased mean 
blood pressure in conscious sodium restricted dogs.
Plasma renin activity (PRA) and plasma aldosterone concentration were 
strongly enhanced in conscious dogs maintained on low-sodium diet. 
Perindopril (3 mg.kg  ^ p.o.) induced a further increase in PRA 
associated with a decrease in plasma aldosterone concentration. The 
degree and duration of ACE inhibition appear to exceed those obtained 
with enalapril and enalaprilat.
* Summary from published pharmacology by Laubie et ^  (116) with 
doses calculated in terms of perindopril base and de-esterified 
S-9780.
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A 1.3 PHARMACOKINETICS**
The pharmacokinetic studies were performed in the rat, dog and monkey
14 -1
using single doses of C-labelled perindopril (0.5 mg.kg i.v. and
P.O.). Absorption from the gastrointestinal tract was rapid, with
maximum concentrations in plasma after one hour in the rat, dog and
monkey. Distribution of radioactivity was wide and was similar for
all three species. The fall in radioactivity after intravenous
administration was triphasic, giving the following biological
half-lives:
Half-life
Rat
hours
Dog
hours
Monkey
hours
1st phase 
2nd phase 
3rd phase
0 .2 + 0.1 
1.5 + 0 . 6  
67 + 42
0 .7 + 0.1 
2.5 + 0.5 
3 4 + 4
0 . 5  + 0.1  
2.1 + 0.3 
42 + 8
A 1.4 TOXICOLOGY**
Acute Toxicity
The LDrm for oral perindopril in the rat exceeded 3000 mg.kg 
50
and in the mouse it exceeded 2500 mg.kg \  The signs of toxicity 
which were seen consisted of diminished motor activity with depressed 
respiration.
215
Sub-acute Toxicity
After 5 weeks’ treatment with increasing oral doses of perindopril, 
the minimum lethal oral dose in rats was found to exceed 1000 mg.kg 
the maximum tolerated dose was 30 mg.kg ^: above this dose,
progressive renal impairment occurred.
In the monkey, the minimum lethal oral dose exceeded 1000 mg.kg ^; 
the maximum tolerated dose was 64 mg.kg
Chronic Toxicity
Three months’ treatment to rats with 1 mg.kg  ^ per day was well
- 1
tolerated, with no evidence of toxicity. Five mg.kg per day 
caused functional renal impairment and 30 mg.kg per day led to 
histological renal damage in 25% of the animals. The equivalent 
pharmacological doses of enalapril and captopril (60 mg.kg  ^ and 
600 mg.kg"”* respectively) caused the same effects but with 
higher incidences.
Monkeys treated for three months with oral perindopril tolerated 
doses of 0.5 and 2.5 mg.kg"^ per day without effect. Treatment 
with 10 mg.kg ”* per day simply resulted in a reduction of body 
weight.
Mutagenicity
Tests for gene or chromosome mutations failed to demonstrate any 
mutagenic activity.
-1
>
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Conclusion
Perindopril may safely be tested in man for periods of up to one 
month with oral administration.
** This information has been kindly supplied by the Institut de 
Recherches Internationales Servier on the condition that it shall not 
be copied or used without their prior written permission.
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A2.1 PHARMACOKINETICS
The data from the oral dosing study were fitted to a one-compartment 
model assuming zero order input (Chapter 7), using the equations 
derived as follows.
Let dose input rate, R = dose / t ^ max
and = amount of drug in the central compartment 
Then assuming first order pharmacokinetics.
dX./dt = R - ke.X^ (1
Taking the Laplace transform.
s.L(X^) - X^(0) = ^  - ke.L(X^
First dose
Since for the first dose, X^(0) = 0, equation (2) gives
s.L(X^) + ke.L(X^) =
l-e- = s.(si ke)
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and by taking the anti-Laplace transform,
X R -ke.t
Since the concentration in the central compartment ([C]) is / V^, 
where = apparent volume of the central compartment.
Since clearance/bioavailability = V^.ke, this can be simplified;
[C] = ( 5 )
At times when t > t_ , let t’ = t - t^„ :max max
dX^/dt' = - ke.X^
giving s.L(X^) - X^(0) = - ke.L(X^
X.(0)
=> L(X ) =    (6)
(s + ke)
and X^ = X^(0).e"k®'t' (7)
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At t’ = 0, i.e. t = t , X.(0) is the same as X.(t ) and can be ’ max 1 1 max
calculated from equation (4) above:
X^(0) = -^.(1 - e"^®'^max) (8)
Substitution for X^(0) from equation (8) into equation (7) gives
and [C] = —^  .(1 - e ^®'^max).e (9)
221
Repeated dosing
After chronic dosing, a further parameter is included representing the 
amount of drug in the central compartment at the time of dosing,
X^(7).
Thus for t < tmax
dX^/dt z R - ke.X^
:> s.L(X^) -X^(7) = — g  ke.L(X^)
:> s.L(X^) + ke.L(X^) = - | - + X ^ ( 7 )
R X.(7)
) = 8.(8 + ke) + (s + ke)
:> X^ = . ( 1  -  e ' R G - t ,  + x ^ ( 7 ) . e " R ® ' t
and [C] = . ( 1  - + [C(7)].e'R®‘'^ (11
Similarly, for t > t^^:
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A2.2 PHARMACODYNAMICS
It has been postulated that the effect on angiotensin converting 
enzyme activity may be modelled using the kinetics of the angiotensin 
converting enzyme inhibitors (17,111). Use of the Hill equation has 
been suggested (111) since this allows for a maximum response of 100% 
inhibition and for the ’sigmoid’ nature of the dose response curve. 
There clearly was a time lag between peak drug concentration and peak 
inhibition of angiotensin converting enzyme in plasma in the case of 
the oral data (Chapters 3 & 7), however, and therefore a separate 
’effect’ compartment was postulated. It was assumed that the 
concentration in this compartment was governed by first order 
kinetics but that the compartment did not in any way alter the 
pharmacokinetics previously described (181,218, Figure 19).
i.e.
Let X„ be the amount of drug in the ’effect’ compartment and the
£j
concentration, [C^], = X^/V^:
dXg/dt = k^g.X^ - keq.Xg
=> s.L(Xg) - Xg(0) = k^g.L(X^) - keq.L(Xg)
X_(0) k_.L(Xj 
giving L(Xg) = --------  + ----------  (13)
(s + keq) (s + keq)
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First dose
For the first dose, Xg(0) = 0. From the kinetics, for t < t^ ^  
after the first dose, equation (3) was
R
L(X,1 s.(s + ke)
Therefore, equation (12) reduces to
R «k
L(X^) = — 7----------  rnrrr (14)E s.(s + ke).(s + keq)
g i v i n g
Y _ , p r 1  1_____ -ke.t__________ 1______  -keq.t -,
E IE* ke.keq ke.(ke - keq)* keq.(ke - keq)*
k^g.R k^g.R g-ke.t ^-keq.t
■ Vg.ke.keq Vg.(ke - keq)**- kë këq ^
Since k^^/V^ = keq/V^, this gives
rn 1 R R r keq.e’*^®*^ _-keq.t -,
= -CÎ + V,.(ke - keq)'[  ki----- ® ’
dXg/dt' z k^g.X^ - keq.Xg
15
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=> s.L(Xg) - Xg(t^g^) = k^g.L(X^) - keq.L(Xg)
From equation (6),
=> (IS'
Substitution of equation (16) into equation (15) gives
  klE-%l'tmax'
E “ (s + keq) * (s + keq).(s + ke)
-  X: = - e—
Therefore, since keq/V^ = k^^/V^,
[0:3 = [ V t _ , - ®-""' '^7,
Repeated closing
After multiple doses, for t < t^^, combining equation (10) with 
equation (13) gives
- l^E'^ l^ ^^ _____________ *^^ 1E_____
E " (s + keq) (s + ke). (s + keq) s.(s + ke). (s + keq)
225
, P r 1  1_____ -ke.t_________ 1_______  -keq.t .
IE" ke.keq ke.(ke - keq)’ keq.(ke - keq)'
and so [Cg] = [C2(7,].e-k®q-t + v^.(kc'-'IIq) ‘ ‘ ®'^''
kig.R kiE-R re-k®'t
+ —--,_T + —-- TT-Z--- \ . L------7— ------- 7-— --JVg.ke.keq Vg.(ke - keq)* ke keq
which can be simplified to
For t > t after multiple doses, [CL(t__ )] and [C(t )] are max E max max
calculated from equations (18) and (12) and are used in equation (17)
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Relationship to ACE inhibition
The drug concentration in the effect compartment, [Cg], was 
related to percentage inhibition of plasma angiotensin converting 
enzyme by using the Hill equation;
100.[C]^
% ACE inhibition = ---
where is the concentration in the effect compartment
which produces 50% inhibition of angiotensin converting enzyme and
y gives a measure of the sigmoidicity of the relationship. The
conventional term, E , is replaced in this case by the known
max
maximum inhibition, i.e. 100%.
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Lees KR & Reid JL (1984) Single and multiple administration of 
an angiotensin converting enzyme inhibitor, S-9490-3, in normo- 
tensive subjects. British Journal of Clinical Pharmacology,
19 (1), 132P - 133P
Lees KR & Reid JL (1985) Effects in normotensive subjects of 
perindopril, an angiotensin converting enzyme inhibitor.
Clinical Science, 69 Supplement 12, 49P
Lees KR & Reid JL (1986) Effects of the angiotensin converting 
enzyme inhibitor, perindopril, in hypertensive patients.
British Journal of Clinical Pharmacology (in press)
Lees KR, Kelman AW, Meredith P & Reid JL (1986) Pharmaco­
kinetics of the angiotensin converting enzyme inhibitor, 
perindopril, after repeated oral dosing. British Journal of 
Clinical Pharmacology (in press)
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